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ABSTRACT 
A novel series of near-infrared fluorescent contrast agents was developed and 
characterized. Their physicochemical and optical properties were measured. By altering functional 
groups of cyanine fluorophores, the selective targeting of endocrine glands, exocrine glands, 
cartilage and bone using NIR fluorescence to visualize the targeted tissue has been reported. These 
agents have high specificity for tissue targeting inherent to the chemical structure of the 
fluorophore. After a single low-dose intravenous injection these agents have high specificity for 
tissue targeting inherent to the chemical structure of the fluorophore. The results lay the foundation 
for future improvements in optical imaging in endocrine surgery, tissue engineering, joint surgery, 
and cartilage-specific drug development. 
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1 Introduction to Real-Time Biomedical Imaging 
While medication for the treatment of human diseases continues to improve, surgery 
remains a central component for many complicated indications.1,2 The ability to fully resect 
tumorous tissue in cancer patients while avoiding vital tissues present in the surgical field 
greatly affects the patient’s long-term survival. The past decade has seen a rapid growth and 
technological advancement of imaging techniques. Computerized tomography (CT), MRI, 
ultrasonography and endoscopy all aid in the presurgical process to ensure the possibility of 
death from surgery is worth the risk for potential cure, but their utility during surgery is 
limited.3 In general, the surgeon must distinguish diseased tissue from normal tissue solely by 
their eyesight and physical analyses, even during complex resections. During surgery, the 
question contemplated by every patient and practitioner is “how do you know if you got it all?” 
Surgeons typically have to submit specimens for histological evaluation and wait for the results 
to determine if additional removal is necessary. 
1.1 Imaging Modalities 
New technologies are revolutionizing the way surgery is performed.4 The medical imaging 
community has pursued various avenues by translating spectral imaging techniques from 
existing preoperative methods to offer surgeons real-time visualization of the surgical field. 
Most of these modalities are tomographic imaging, including single photon emission computed 
tomography (SPECT) or positron emission tomography (PET).5 Of the two, SPECT is more 
widely used as providers have more access to machines and protocols for acquisition, 
processing, and reporting. PET offers further advantages over SPECT, such as improved image 
quality, greater interpretive certainty, higher diagnostic accuracy, lower exposure to radiation, 
and shorter imaging times through its use of positron-labeled molecules in smaller doses. While 
both of these have had some success, nonspecific uptake of radioactive tracers leads to a less 
distinguishable signal rendering the surgical field still challenging to interpret. In addition, 
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these tracers involve the use of deep penetrating radioactivity limiting the overall potential of 
their real-time translation due to their short lifespan which can be shorter than one hour. This 
can require the contrast agents to be injected multiple times during a surgery exposing the 
patient to higher amounts of damaging radiation. The use of these radioactive tracers can be 
the equivalent of anywhere from 2-250 x-rays.6 Due to the need for lead collimators to make 
SPECT imaging 3D, it has a very low detection efficiency (<10-4 times the number of emitted 
gamma rays).7 The subsequent use of reconstruction algorithms to visually generate the spatial 
distribution of signal sources allows for limited spatial resolution and poor temporal 
resolution.8 
 
Figure 1.1. Absorbance of water, hemoglobin and oxyhemoglobin highlighting the NIR window 
from 650-900 nm 
 
Intraoperative fluorescence imaging or fluorescence-guided surgery (FGS), can provide 
high fidelity visualization for real-time localization, resection and margin confirmation in 
surgery9 without the use of ionizing radiation. FGS relies on the emission of light through 
fluorescence for illumination and an imaging system to assist surgeons in distinguishing 
different tissues through the injection of fluorescent detection agents. The disadvantages of 
FGS are the tissue penetration depth and autofluorescence. As a result, fluorescence imaging 
in the visible spectrum hinders resolution and contrast with increasing tissue depths. As shown 
in Figure 1.1, the NIR range from about 650-900 nm is useful due to low autofluorescence and 
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scattering from tissues. Tissue penetration by this light is enhanced in this range due to low 
tissue florescence and absorption from hemoglobin and can reach a penetration depth of almost 
1 cm as shown in Figure 1.2. Based on tissue penetration depth, a high signal-to-background 
ratio (SBR) is required. 
 
Figure 1.2. Effective penetration depth of light 
1.2 Fluorescence Guided Surgery Technology 
Many groups have invested in developing imaging systems for NIR FGS over the past 
few years10-23 and now some of these systems have been applied clinically. These systems can 
be classified as portable, functional and endoscopic, and laparoscopic. Many of these systems 
have already been utilized in clinical diagnosis and treatment. These different types of systems 
offer distinct advantages such as operation convenience, improved image assessment and 
increasing detection depth. At least three of these systems have already been approved by the 
FDA. 
Portable FGS systems satisfy the criteria for convenient operation. Hammamatsu’s 
Photodynamic Eye (PDETM) is an FDA approved handheld imaging system that emits NIR 
light and detects it through the in vivo uptake of fluorescent 2D images. Additionally, the FDA 
approved ArtemisTM system includes intraoperative visible images to give an overlay providing 
excellent utility for nerve surgeries.24,25 A third FDA approved portable system is the SPY 
system that has been applied to monitor skin perfusion in nipple-sparing mastectomies.26 
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The Fluorescence Assisted Resection and Exploration (FLARE) system developed by 
the Frangioni lab at Harvard Medical School is characterized as a functional intraoperative 
system.27 It uses three cameras to simultaneously collect images from two NIR channels (700 
and 800 nm) and one visible channel, exploiting the large NIR wavelength window and 
theoretically allowing for a disease-targeted fluorophore to be distinguished from another 
contrast targeting vital tissues. The FLARE system has successfully been applied to sentinel 
lymph node mapping in breast cancer,28 cervical cancer,29 and vulvar cancer patients.30 
Although this system is not portable and has a large hardware footprint, a mini FLARE system 
has also been developed.28 
 
Figure 1.3. Schematic of dual channel intraoperative imaging 
 
Recently, this technology has been applied to the surgical removal of liver metastases, 
breast cancer, ovarian cancer, melanoma, vulvar cancer, and cervical cancer, but an additional 
part of this is targeting healthy tissue that should be avoided during surgery. With the help of 
FGS technology, the prognosis of patients will undoubtedly improve. For example, Loja et al. 
used FGS with Alexa-647 labeled pH Low Insertion Peptide, pHLIP (a pH responsive peptide), 
to detect alterations in extracellular pH in head and neck squamous cell carcinoma in order to 
assess tumor margins during surgery, improving the prognosis of this cancer through better 
detection. 
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In recent years FGS has been coupled with endoscopic and laparoscopic technology to 
work around the issue of penetration depth. These systems have been applied to cancer surgery 
and have assisted in minimally invasive cancer therapy.31 Disadvantages to these systems are 
determining the optical path length to simultaneously view both visible and NIR fluorescent 
images. It is also difficult to alter the workflow procedure to integrate the FGS technology. 
Glatz et al. developed a color and NIR fluorescence laparoscopy system for the identification 
of tumor margins.32 Another laparoscopic system, the Fluoscope developed by Harvard 
Medical School, is currently recruiting participants for clinical trials for sentinel lymph node 
mapping in lung cancer. 
 
Figure 1.4. High tech goggles help a surgeon visualize cancer cells. Image reprinted with 
permission Washington University School of Medicine in St. Louis/Siteman Cancer Center 
 
Most recently, a goggle system with metal-oxide-semiconductor and a see-through 
display has been developed by the Achilefu lab at Washington University, shown in Figure 1.4. 
This is the first application of a dual-modal see through display in NIR fluorescence imaging. 
The goggles include light source, control, detector and display modules with an 830 nm 
emission filter and can detect a fluorescence signal as low as pM concentrations.23 
1.3 Contrast Agents  
The most important components of FGS technology are the surgical navigation system 
and the imaging contrast agents. The surgical navigation system is required to activate these 
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fluorophores with NIR light and detect their fluorescence on a live video screen for accurate 
surgical guidance after image registration processing by a computer.11  
Because fluorescence is only one pathway that an excited photon can return to lower 
energy, the chemical structure of contrast agents must be designed such that fluorescence is the 
dominant relaxation pathway resulting in a high quantum yield of photon emission. They 
should also have a high molar absorptivity; thereby giving the agents a higher molecular 
brightness. Agents should be specific and cleared quickly from non-target areas to give a lower 
background signal. There are three ways that a dye can target specific tissues; active targeting, 
activatable targeting, and passive targeting. Active targeting involves conjugation of a contrast 
agent to a targeting moiety.33 The success of approach is dependent on several engineering 
obstacles. Most importantly is the choice of and overall efficacy of the targeting ligand. Next 
a satisfactory contrast agent must be chosen with high molecular brightness and fast clearance 
(before ligand attachment).34 Lastly, and the often overlooked is the isolating linker. The linker 
must be flexible enough to allow the targeting ligand to bind and chemically inert so as to avoid 
interactions with the targeting ligand, contrast agent, or binding site. It is also important to 
utilize the linker to optimize the physicochemical properties of the of the entire molecule. 
While this rapid process offers the potential for high SBR, the introduction of a large dye into 
the structure of a targeting moiety often alters its properties causing it to no longer specifically 
target. An activatable contrast agent is one in which the contrast agent’s fluorescence is 
quenched until a particular stimulus (i.e., pH, enzyme, redox potential) alters the structure of 
the agent activating its fluorescence. Passive targeting, also referred to as structure inherent 
targeting relies on the biodistribution of the contrast agent to be selective. The biodistribution 
of a contrast agent can be due to the size, hydrophobicity (often measured as logD or logP), 
molecular recognition, and/or permeability of the tissue. This structure inherent targeting 
allows for the smallest agents and the avoidance of obstacles to active and activatable targeting.  
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1.3.1 FDA Approved Contrast Agents 
 
Figure 1.5. Chemical structure of FDA approved NIR contrast agents 
 
There are currently two NIR contrast agents that have been approved by the Food and 
Drug Administration (FDA); the cyanine dye indocyanine green (ICG) and the phenothiazine 
methylene blue (MB), shown in Figure 1.5. These contrast agents have been used in 
intraoperative imaging for the treatment of sentinel lymph node mapping,10,28,35,36 hepatic 
micrometastases detection,37 and the visualization of the gastrointestinal tract, bile duct, and 
ureters.10,38-42 However, both of these agents display strong non-specific binding to proteins in 
vivo and are not selective. The inability to selectively target specific tissues has limited their 
usefulness in application. In addition, the structures of ICG and MB are such that it cannot be 
covalently conjugated to targeting moieties without significant alteration of the core structure.43 
Methylene blue has mediocre optical properties compared to other contrast agents. In serum 
MB displays a molar absorptivity of 71,200 M-1cm-1 and a quantum yield of 3.8% owing to a 
molecular brightness of 2,706 M-1cm-1. In comparison cyanine dyes such as ICG typically 
display molar absorptivities above 100,000 M-1cm-1 (121,000 M-1cm-1 for ICG in serum) and 
quantum yields closer to 10% (9.3% for ICG). This will be discussed in more detail in Chapter 
3. 
While the imaging community generally agrees that MB and ICG are not ideal 
fluorophores, they are presently the only NIR fluorophores that have been FDA approved. 
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Numerous imaging systems have been developed but there is clearly a need for the 
development of new and better fluorophores to provide the best clinical options for both 
patients and surgeons. 
  
9 
 
2 SYNTHESIS OF A LIBRARY  
2.1 Cyanine Dyes 
Significant advancements are being made to develop NIR-fluorescent compounds that 
target specific tissues and help surgeons to visualize them in real time without changing the 
overall look of the surgical field. A class of dyes that has shown outstanding promise in the 
area of NIR-fluorescence image-guided surgery are cyanine dyes. These dyes, first discovered 
in 1856,44 display a range of absorption and fluorescence covering the electronic spectrum from 
the ultraviolet to the infrared. Due to their extreme sensitivity to light, their inconceivable value 
was not discovered for another 20 years when they were used to increase sensitivity of the 
photographic plate.45 Since then cyanine dyes have been used in an incredible amount of 
applications including but not limited to laser printing,46 pH sensing,47 data storage,48 and 
medicine.49 
Cyanine dyes are distinguished from other dyes in that they possess two nitrogen 
containing heterocycles that are connected by an electron-deficient conjugated methine bridge 
as shown by the general structure in Figure 2.1.50-52 This causes the cation to be delocalized 
throughout the conjugation and is the cause of their high absorption and fluorescence 
wavelengths. 
 
Figure 2.1. General Cyanine Dye Structure 
 
The heterocycles act as both electron donors and acceptors creating an electron 
deficient system throughout the molecule that gives cyanines a wide range of absorption and 
fluorescence in the visible and infrared regions. They are also characterized as having narrow 
absorption bands and high extinction coefficients.2 Their names depend on the how many 
methine groups are found in the bridge connecting the two heterocycles. Dyes containing n = 
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0, 1, 2, and 3, are classified as mono-, tri-, penta-, and hepta-, respectively. There are multiple 
well described routes to the synthesis of monomethine and trimethine cyanines,53 but 
pentamethine and heptamethine cyanines have one general route. This route is through the 
condensation of methylsubstituted quaternized heterocyclic compounds with an α,ω 
dialdehyde or its equivalent.50,53-56 
Their narrow absorption bands and high extinction coefficients are important properties 
that have allowed them to be used in various applications over the last 140 years. Monomethine 
and trimethine cyanines typically fluoresce in the 500-600 range of the electronic spectrum and 
the addition of each double bond to the methine chain causes a bathochromic shift of about 100 
nm resulting in fluorescence around 700 nm for pentamethine and around 800 nm for 
heptamethine cyanines. These wavelengths are ideal for the 700 and 800 nm cameras of the 
FLARE imaging system. These compounds have appealing optical properties including their 
red-shifted fluorescence and elevated quantum yields. 
 In addition to excellent optical properties, cyanines are highly modifiable. As discussed 
previously, their absorption and fluorescence wavelengths can be tuned by modifying the 
length of the methine bridge. Besides the length of the methine bridge, the N-alkyl groups 
(Figure 2.2 blue circle) can be modified to add or reduce hydrophilicity. This position has little 
effect on optical properties, but lipophilicity can be introduced by adding large hydrophobic 
groups such as propyl phenyls or decyls while hydrophilicity can be introduced by the addition 
of charged groups such as quaternary ammoniums or sulfonates. A middle ground can be found 
in compounds including a quaternary pyridinium group that adds water solubility while 
keeping hydrophobic character. In addition functionality can be introduced in this position such 
as alcohols, carboxylic acids, esters, sulfonates, etc. The heterocycle (Figure 2.2 red) can be 
altered to introduce small wavelength changes of a few nm such as from a benzothiazole to a 
3,3-dimethylindolenine or larger wavelength changes up to 100 nm as seen when a quinoline 
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or benz[c,d]indole is introduced. These flatter more conjugated heterocycles also have large 
influences on fluorescence which need to be taken into account as they oftentimes have lower 
quantum yield if they are even fluorescent at all. These heterocycles can also be substituted 
(Figure 2.2 yellow), often with electron donating or electron withdrawing substituents that have 
small effects on the optical properties of the compounds but can have large effects on binding. 
The meso-carbon atom can have substitutions on it as well. Most commonly a halogen is seen 
at this position which is useful for further addition to the cyanine scaffold, but using different 
intermediate salt linkers, alkyl or aromatic groups can be introduced directly to the methine 
bridge. Nucleophiles such as amines, alcohols and thiols can be attached by substitution 
reactions and organoboronic acids can be used to achieve carbon-carbon cross coupling. Lastly, 
a cycloalkene (Figure 2.2 purple) is often introduced on the methine bridge in heptamethine 
dyes for additional stability. This is generally done with a cyclohexene, which has little effect 
on optical properties, but has been done with cyclopentene and cycloheptene as well. The 
cyclopentene greatly alters the angle of the bonds in the methine bridges and causes a large 
redshift in absorption wavelength. 
 
Figure 2.2. Modification sites on cyanine dyes 
 
These properties along with low tissue autofluorescence and the ability to deeply 
penetrate tissue in the NIR window have allowed cyanine dyes to be promising for use in in 
vivo imaging.1,3 Fluorescence imaging techniques with near-infrared dyes are generally 
superior in terms of sensitivity and selectivity. Due to the rigidness of near-infrared dye 
fluorophores during binding, fluorescence increases significantly. Commonly, near-infrared 
emission agents are conjugated with ligands that are known to target specific tumors, but these 
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agents’ application have been limited due to problems with delivery and specificity. Employing 
near-infrared dyes as contrast agents in optical imaging, a non-radiative technique,4 is safer 
than current radiological techniques, however, the applications of cyanine dyes in cancer 
diagnosis and detection is yet to be fully explored.5 
While many groups are currently working on cancer specific contrast agents, it is the 
objective of this work to synthesize contrast agents that are tissue specific. This has dual 
purposes; first because the FLARE system uses two detection cameras, the tumor specific 
contrast agents can be used to label vital tissues that need to be avoided during surgery, but 
also can be used if the specific tissue is the surgical target. 
Our lab has previously synthesized a series of pentamethine cyanines and their 
biodistribution was studied in vivo. This series could specifically target pituitary glands, 
pancreas, and lymph nodes with dependence on molecular characteristics.57,58 Through this 
series, it has been shown that targeting can be predicted by correlating physicochemical 
properties to where the dyes localize in mice. For instance, the optimal logD value for targeting 
the thyroid gland was determined to be between 3.5 and 6.5.57 Before synthesis of the library 
of heptamethine compounds, tables were designed comparing physicochemical properties, 
such as logD, hydrogen bond donors and acceptors, molecular weight, and volume. Table 2.1 
is an example of one of these tables presenting how altering the heptamethine linker can affect 
these properties. Shown in this table are proposed dyes (Figure 2.3) with very small 
modifications made to the structure either on the methine bridge or as a substituent on the 
heterocycle all with N-methyl alkyl chains. These small changes allow the molecular weight 
(mw) of the compounds to be varied from 409 to 641 with an average mw right around 500. 
They are hydrophobic compounds with logD ranging from 4.0 to 6.6. None of them have any 
hydrogen bond donors, but they all have between 1 and 4 hydrogen bond acceptors. This table 
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shows how widely the small changes in these compounds can affect their physicochemical 
properties and thereby could also affect their biodistribution. 
Table 2.1 Physicochemical properties of select proposed dyes 
Dye mw LogD volume rotatable 
bonds 
dipole H bond 
donors 
H bond 
acceptors 
polarizability 
26a 409.59 4.08 407.63 4 6.55 0 1 51.06 
27a 484.10 5.15 470.2 3 27.81 0 2 57.83 
27e 544.15 4.84 524.01 5 30.7 0 4 62.82 
27f 641.89 6.69 507.28 3 28.27 0 4 63.14 
28a 470.07 4.71 452.09 3 29.03 0 2 55.98 
28b 498.13 5.60 488.97 3 25.48 0 2 59.68 
29a 528.55 5.34 474.58 3 27.8 0 2 58.5 
30a 463.68 5.24 475.16 3 25.45 0 1 57.93 
30f 525.75 6.37 528.7 4 25.07 0 1 65.73 
31a 560.20 6.58 542.83 4 28.46 0 2 67.38 
 
 
Figure 2.3 Select proposed dyes for physicochemical property calculations 
2.2 Modification of Heterocycles 
Toward creating a library of cyanine dyes for biodistribution screening, optimized 
routes for altering the structure of the cyanine pharmacophore have been developed. The 
synthesis of cyanine dyes begins with the Fischer indole cyclization reaction of various 
phenylhydrazines 1a-f with 3-methyl-2-butanone in acetic acid.59-61 This provides 2,3,3-
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trimethylindolenines 2a-f in very good yields as shown in Equation 1. The yields range from 
80-91% by conventional methods but our group has shown that 100% yield can be obtained 
using microwave.62 By altering the substituents on the phenylhydrazine the heterocyclic 
substituents of the final cyanines can be modified. The inclusion of sulfonate groups can make 
the dye water soluble, while a methoxy substituent will redshift the wavelength about 10 nm.  
 
2.3 Quaternary Ammonium Salts 
As shown in Equation 2, these 2,3,3-trimethylindolenines 2a-f as well as 1,1,2-
trimethyl-1H-benz[e]indole are alkylated by refluxing various alkyl halides or sultones in 
acetonitrile to prepare quaternary ammonium salts 3a-t which are precipitated in ether. These 
compounds are synthesized in fair to excellent yields ranging from 50% to 91%. The yields are 
typically lower for compounds 3h-k with the additional quaternary ammonium ranging from 
50% to 81%. These compounds use 3-bromopropyltrimethylammonium bromide as starting 
material which also precipitates in either and makes the purification more difficult. Compounds 
3l-o also tend to have lower yields ranging from 56% to 80% due to reaction kinetics. However 
by conventional methods these reactions typically are not completed overnight. By using 
microwave excellent yields of 98% can be achieved in minutes.62 
15 
 
 
Another heterocyclic modification is described in Scheme 2.1. Benz[c,d]indole 
quaternary salts are formed by first alkylating benz[c,d]indol-2(1H)-one 4 before thionation 
with phosphorous pentasulfide in boiling pyridine. The thioketone 6 is then methylated to a 
thioether by stirring with iodomethane overnight at room temperature. The thioether 7 is then 
replaced by Meldrum’s acid by heating for 6 hours under basic conditions in ethanol. Last, the 
Meldrum’s acid is removed by dissolving compound 8 in acetic acid and refluxing for 20 
minutes. Hydrochloric acid is dripped into the solution before cooling to room temperature 
forming the acidic methyl position on the benz[c,d]indole quaternary ammonium salt 9.63 
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Scheme 2.1. Synthesis of benz[c,d]indole quaternary salts 9a-b 
2.4 Methine Linkers Modification 
In parallel to quaternary salt formation, intermediate salt linkers are synthesized. To 
obtain the linker used for the development of pentamethine cyanines containing a meso-
halogen mucochloric or mucobromic acid 10 was reacted with aniline in warm ethanol and 
upon cooling and dilution with diethyl ether, the intermediate salt linker precipitated as a 
yellow solid 11 (Equation 3).  
 
 Another pentamethine linker was synthesized through a Vilsmeier formulation on 
bromoacetic acid as shown in Equation 4.64 Phosphorous oxychloride (POCl3) was added 
dropwise to a cooled solution of DMF at 0 °C which causes the solution to turn a pale orange 
color. After allowing the solution to warm to room temperature bromoacetic acid 12 was added 
in portions and heated overnight at 70 °C. The reaction was then quenched with water and the 
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pH increased to 9 with sodium carbonate before filtration of inorganic salts and extraction of 
triformyl methane 13. This linker allows for the formation of pentamethine cyanines with an 
aldehyde at the meso-position. 
 
As shown in Equation 5, the heptamethine linkers are synthesized through a similar 
Vilsmeier reaction. Substituted or unsubstituted cyclohexanones 14 in dichloromethane were 
added dropwise to the POCl3 mixture at 0 °C. The solution was then heated at 100 °C for 2 
hours and cooled to room temperature. The dimethyliminium is trapped with aniline to increase 
long term stability before being precipitated in water with hydrochloric acid as Vilsmeier 
reagents 15.  
 
 The same procedure can be used with cyclopentanones 16a or cycloheptanones 16b to 
change the size of the cyclohexene in the methine bridge as shown in Equation 6. The inclusion 
of a cyclopentanone redshifts the wavelength of the final dyes to about 820 nm due to the strain 
put on the methine bridge by the cycle. 
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 When cyclic ketones are utilized for the formation of the Vilsmeier reagents 15 and 17 
halogens are installed in the meso- position that allow for further conjugation of the dye to 
nucleophiles by substitution or carbon-carbon coupled through Suzuki coupling. By preparing 
Vilsmeier reagents 19a-b with methyl and phenyl substituents in the meso- position from 1-
substituted cyclohexenes, Suzuki coupling of the dye can be avoided later. 
 
2.5 Monomethine Cyanine Preparation 
As described by our lab, the benz[c,d]indole heterocycle redshifts the wavelength about 
100 nm.65,66 Although these dyes are usually not fluorescent, it has been shown that when they 
have restricted rotation such as in a viscous solvent or bound to a biomolecule they will 
fluoresce. While the fluorescence of monomethine cyanines is generally around 500 nm, 
monomethine cyanines including two of these benz[c,d]indole heterocycles fluoresce in the 
near infrared region. They are formed by heating quaternary ammonium salt 9b (Scheme 2.1) 
with thioketone 7b in acetonitrile in the presence of triethyl amine for 2 hours as shown in 
Equation 8. Dye 20 was synthesized in 72% yield after purification by column chromatography 
and would fluoresce at 700 nm. 
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2.6 Trimethine Cyanines 
Trimethine dyes typically fluoresce in the visible region, but their wavelengths can 
correspondingly be shifted using the benz[c,d]indole heterocycle.67 As shown in Equation 9, 
symmetrical trimethine cyanines are formed by heating quaternary ammonium salts with 
triethyl orthoacetate in acetic anhydride for 2 hours. The dyes are precipitated out of solution 
and washed with ether. This synthesis pathway has been optimized to yield pure dyes with no 
further purification and dye 21 was synthesized in 76% yield. These symmetrical trimethine 
cyanine dyes containing two benz[c,d]indole heterocycles fluoresce around 780 nm and would 
be useful with the 800 nm camera of the FLARE system. 
 
 
A trimethine cyanine dye containing only one benz[c,d]indole heterocycle would also 
fluoresce in the NIR region ~680 nm and would be useful with the 700 nm camera of the 
FLARE system. As shown in Scheme 2.2 the key step in the synthesis of unsymmetrical 
trimethine cyanines is the formation of an aldehyde 22 by Vilsmeier formulation on a 
quaternary ammonium salt.68,69 This aldehyde can then be reacted with another salt to form an 
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unsymmetrical trimethine cyanine. This synthesis pathway has also been optimized to yield 
pure dyes with no further purification. Dye 23a was synthesized in 55% yield while dye 23b 
was synthesized in 79% yield. 
 
Scheme 2.2. Synthesis of unsymmetrical trimethine cyanines 23a-b fluorescing in the NIR region 
2.7 Pentamethine Cyanines 
The major synthetic route to pentamethine cyanines generally involves condensation of 
quaternary ammonium salts with malondialdehyde derivatives. This reaction generally takes 
place in acetic anhydride in the presence of sodium acetate as shown in Equation 10. Four new 
pentamethine cyanines with a meso-chlorine atom were synthesized and purified by column 
chromatography with yields ranging from 68%-82%. 
 
  
The pentamethine cyanine with a meso-aldehyde was synthesized through the 
condensation of triformyl methane 13 with quaternary ammonium salt 3b. Sodium acetate was 
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not strong enough for this reaction and therefore pyridine was used in ethanol as shown in 
Equation 11. Dye 25 was purified by column chromatography in 65% yield. 
 
2.8 Heptamethine Cyanines With an Open Chain 
The use of heptamethine cyanines as fluorescent markers in biological systems has 
generated enormous interest. The general synthetic route is similar to that of pentamethine 
cyanines. Heptamethines are formed by heating individual quaternary ammonium salts 3 with 
intermediate linkers in acetic anhydride for 2 hours in the presence of sodium acetate as shown 
in Equation 12. These dyes range in yield from 15% to 90%. Tricationic dyes 26h-k were 
responsible for many much of the lower yields ranging from 15% to 62% as they are more 
difficult to purify and large amounts of dye are lost in recrystallization or during reverse phase 
column chromatography. The methoxy dyes also have lower yields potentially due to more 
rapid decomposition. After the pure dye eluted from the column, brown decomposition could 
be seen and these dyes were synthesized in yields ranging from 47% to 86%. The rest of the 
dyes with no substitutions or electron withdrawing substitutions were synthesized in yields of 
60% to 90%. 
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The mechanism for heptamethine cyanines has been described as shown in Scheme 2.3. 
The reaction is started with deprotonation of the quaternary ammonium salt by the acetate anion 
from sodium acetate. The mechanism is similar for pentamethine cyanines, but with two less 
carbons in the methine linker. 
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Scheme 2.3. Mechanism of heptamethine cyanine formation 
 
Pentamethine and heptamethine cyanine synthesis often does not go to completion and 
therefore requires more rigorous purification. The optimal method for purification of these 
compounds is through a reprecipitation process which involves dissolving the compounds in a 
minimal amount of warm methanol before being precipitated in ether. Column chromatography 
is necessary for dyes that cannot be purified through these precipitation processes. 
Hydrophobic dyes usually elute in dichloromethane with 1-5% methanol. Dyes containing 
multiple charges such as 26h-k tend to be more difficult to purify. They are generally purified 
by reverse-phase column chromatography using commercially available C18 silica gel that can 
be costly. Crystallization of highly polar cyanines has previously seldom furnished pure 
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compounds. Our lab has shown that these compounds can easily be recrystallized in good yield 
after dissolving in water and precipitating with acetone (1:50) or from dimethyl sulfoxide with 
ethyl acetate (1:100). 
2.9 Heptamethine Cyanines Containing a Cyclic Ring in the Methine Chain 
Many heptamethine cyanines have been designed to contain a six-membered 
carbocyclic subsystem as part of the methine chain such as in compounds 27. This subsystem 
increases the rigidity of the molecule typically increasing the stability of these compounds and 
decreasing aggregation in solution. As shown in Equation 13, a set of eleven heptamethine 
compounds containing a cyclohexene ring and meso-chlorine atom were synthesized. These 
dyes are used for modifications described in Section 2.10. These dyes were synthesized in 
yields ranging from 66% to 84%. 
 
 Another class of heptamethine dyes with cyclopentane or cycloheptene in the methine 
bridge were synthesized. Alteration of a molecule to a similar but more planar and rigid 
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molecule often increases the quantum yield of fluorescence.70 A five-membered ring would 
further increase rigidity and increase quantum yield while a seven-membered ring would allow 
additional flexibility while still preventing rotation around the methine bridge in the fused 
positions. These two heptamethine cyanines are prepared following a similar reaction as shown 
in Equation 14. Because of the increased rigidity of the methine bridge caused by the five-
membered ring, the reaction to 28a did not go to completion and was purified by column to a 
53% yield. Dye 28b was also purified by column in a 79% yield. 
 
 Heptamethine cyanines bearing a bromine in the meso- position could undergo Suzuki 
coupling reactions with organoboronic acid reagents to give dyes substituted in this position.71 
These heptamethines with a meso-bromine 29 are synthesized using Vilsmeier 15b as described 
in Equation 15 and were synthesized in 74% and 65% yield for 29a and 29b, respectively. 
 
 As mentioned previously, this Suzuki coupling step with organoboronic acids can 
potentially be avoided by using Vilsmeier reagents 19a-b as shown in Equation 16. Here 
heptamethine cyanines with meso-methyl and phenyl groups were synthesized by condensation 
of quaternary ammonium salts 3 with methyl and phenyl substituted Vilsmeier reagents 19a-
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b. To do this using Suzuki coupling, methylboronic acid or phenylboronic acid would be 
reacted with the chloro- or bromo-substituted dye with an expensive palladium catalyst. In 
addition, this has generally only been done with water soluble dyes. The carbon-carbon coupled 
final dye must then be separated from the starting material dye by column chromatography. 
Dyes 30a-j, synthesized by reacting the corresponding quaternary ammonium salts 3 with 
Vilsmeier reagents 19a-b, are purified solely by washing with methanol and were synthesized 
in 63-85% yield. 
 
 Modification of the heterocycles has focused almost entirely on the meso- position of 
the methine bridge. There is a lack of literature modifying other sites of the cyclic ring on the 
bridge. An example of another point of modification is 5 position of the cyclohexene as shown 
in Equation 17. This position is not conjugated into the system and therefore allows for 
modification of the structure and hydrophobicity with less effects on optical properties. The 
dyes were substituted in very good yields above 80%. 
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2.10 Modifications to the Heptamethine Core 
Because these broadly used fluorophores suffer significant drawbacks such as poor 
stability, likely due to nucleophilic exchange reactions at the meso- position, cyanines modified 
at this position are desirable.72 The chlorine atom at this position of heptamethine dyes allows 
for conjugation to various nucleophiles, such as phenols, through the SRN1 displacement 
pathway. This differs from regular nucleophilic substitutions in that deactivating groups are 
not necessary. These substituted compounds should be more stable while maintaining excellent 
optical and physical properties, however they have rarely been synthesized. For oxygen 
attachments to the cyanine core, sodium hydride (NaH) is used to generate the phenoxide ion 
in situ because the protonated oxygen exhibits limited nucleophilicity73 as shown in Equation 
18. A small shift in maximum absorption wavelength from 776 nm to 762 nm was observed. 
Dye 32 was synthesized in 81% yield. 
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Aromatic amines are more difficult to couple via conventional amide-coupling 
strategies because of electron delocalization across the ring and therefore required microwave 
heating as described in Equation 19. The reaction would not proceed by conventional methods 
due to the instability of cyanine dyes and heat and time required for the reaction to take place. 
Optimal microwave conditions were determined by small scale reactions followed by UV-Vis 
spectroscopy as described in Table 2.2 before scaling up for purification. Optimization began 
by heating at 100 W and increasing the time. After 20 minutes, crude yield began decreasing. 
The temperature was then increased which also decreased the crude yield, but decreasing the 
temperature to 80 °C increased crude yield. Trial 6 was determined to be the optimal conditions 
achieving a 72% yield. 
 
Table 2.2. Optimization of microwave conditions for nucleophilic addition of amines 
Trial Reaction Time 
(min) 
Temp (°C) Power 
(W) 
Yield 
(%) 
1 5 100 100 32 
2 10 100 100 46 
3 20 100 100 61 
4 40 100 100 54 
5 20 120 100 51 
6 20 80 100 72 
7 20 80 120 62 
8 20 80 80 55 
 
In order to synthesize a dye containing a sulfonazide, acetylaminobenzene was first 
sulfonated using chlorosulfonic acid. The acid was then converted to a sulfonyl chloride using 
thionyl chloride. The sulfonazide was then formed through nucleophilic substitution of the 
chlorine with sodium azide, before deprotection of the amine using hydrochloric acid. The 
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aromatic sulfonazide was more difficult to couple via conventional amide-couple strategies and 
microwave heating was necessary. The optimized microwave method described in Table 2.2 
was used. This dye was purified by column chromatography using 0.2% methanol in 
dichloromethane as the eluting solvent. Dye 39 was synthesized in 46% yield. 
 
Scheme 2.4. Synthesis of a heptamethine cyanine 39 with sulfonazide  
 
2.10.1 Smiles Rearrangement 
To synthesize a highly charged heptamethine cyanine a Smiles rearrangement was 
utilized. Smiles rearrangements require both strong bases and elevated temperatures to drive 
the α,δ-transposition of heteroatoms to the thermodynamically preferred isomer. A distinct 
alternative selectively integrates an electrophile on the heteroatom originally attached to the 
unsaturated carbon providing otherwise unreachable products allowing for more simple access 
to meso-oxygen substituted heptamethine cyanines from more facile tertiary amino precursors. 
This method is able to counteract the disadvantages of the more conventional attachment of 
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alkoxides.72 The meso-aliphatic oxygen substitution provides the opportunity to develop agents 
with improved properties relative to those prepared through current strategies. Here, an 
additional positive charge is added to a hydrophobic heptamethine cyanine to make it more 
hydrophilic. As shown in Scheme 2.5, the secondary amine N-methylethanolamine was first 
attached to the dye by heating in a sealed tube. Characteristically this nitrogen addition to the 
methine chain causes blue-shifted absorption of about 100 nm, a broad spectrum, and a larger 
Stokes shift. Upon Smiles rearrangement to the oxygen substitution by microwave heating, a 
visible blue to green color transition occurs as the maximum absorption wavelength shifts to 
762 nm along with a smaller Stokes shift and greater molar absorptivity. In order to synthesize 
a dicationic heptamethine cyanine, iodomethane was included in the Smiles rearrangement 
reaction to quaternize the amine. Dye 41 was synthesized in 70% yield. 
 
Scheme 2.5. Smiles rearrangement on heptamethine cyanine 40 
 
2.10.2 Suzuki Coupling 
Another common method of preparing monofunctional cyanines is through the stepwise 
conjugation of two different heterocycles with one of these heterocycles containing 
monocarboxy functionality, but this approach is problematic due to difficult purification of 
from the undesirable symmetrical dyes that form.71 In addition, the ether, thioether and amide 
linkages are chemically labile rendering the fluorophores susceptible to cleavage. To avoid this 
problem, a direct carbon substitution is preferable. Organoboronic acids are convenient 
reagents for cross coupling reagents due to their thermal stability and lack of reactivity with 
water. Hydrophilic chloro-substituted heptamethine cyanines have been carbon-carbon 
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coupled rarely, and cross coupling has been seen even less with hydrophobic cyanines.71 The 
reaction of chloro dye 27a and an arylboronic derivative in a mixture of DMF and water in the 
presence of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) allowed the reaction to 
proceed as shown in Equation 20. The dye was synthesized in poor yield of 21% due to the 
reaction not working well with water insoluble compounds. The absorption spectra of dye 42 
shows characteristic broadening and a hypsochromic shift of ~20 nm indicating a direct 
interaction of the aryl group with the chromophore system similar to dyes 30f-j with a phenyl 
ring attached at the meso- position. 
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3 TARGETING  
Through a collaboration with the Choi lab at Harvard Medical school, an initial screen 
of the synthesized NIR fluorophore library injected IV into CD-1 mice identified three potential 
pharmacophores for endocrine uptake with emission wavelengths of 700 and 800 nm. The 
endocrine glands are tissues of considerable clinical importance, yet they are problematic to 
locate during surgery. 
3.1 Adrenal Gland Targeting 
The adrenals glands (AGs) are paired endocrine glands that produce hormones such as 
epinephrine, norepinephrine, androgens, estrogens, aldosterone, and cortisol. They are also the 
site of benign and malignant tumors that can lead to Cushing’s syndrome, Conn syndrome, 
virilization, and feminization.74 Radical adrenalectomy is traditionally performed by 
conventional open surgery. However, since its initial description in 1992, laparoscopic 
adrenalectomy has expanded significantly for the resection of functional adrenal tumors and 
incidentalomas smaller than 8-10 cm.75,76 The advantages of a laparoscopic approach include 
a better cosmetic result, shorter recovery time, and significantly less pain, while it may cause 
shorter survival, less complete removal of the tumor, and shorter time to and a greater chance 
of the tumor returning.77 In addition, laparoscopic instruments could rub against the tumor 
during surgery and allow tumor cells to spread to other parts of the abdomen. Real-time image 
guidance during the AG surgery can help guarantee a complete removal of the tumor while 
preserving vital tissues neighboring the glands, which is also key to shortening intraoperative 
time and effort.78-80 
It was reported by Obermeyer et al. that visualizing the AGs after a single intravenous 
injection of methylene blue (MB) shortened the operative time of laparoscopic 
adrenalectomy.81 However, the use of MB is not efficient because color visualization demands 
high dose injections, while retention time in the target is too short for surgery. Indeed, the 
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effective dose of MB used for the aforementioned pig study was 7.5 mg/kg, which is 5-fold 
higher than the typical clinical dose (1.5 mg/kg). In addition, the duration of bluish color 
changes in the AG was less than 15 min.81 
3.1.1 Optical and Photophysical Properties 
The two novel, high performance NIR fluorophores 24c and 26e that were identified 
from the library of ~100 compounds through screening that target the AGs, emit at 700 nm and 
800 nm, respectively. Their structures can be seen in Figure 3.1. In this study, their performance 
was compared, quantitatively, to MB and ICG in both small and large animal models of AG 
surgery. After initial screening, 24c (700 nm NIR) and 26e (800 nm NIR) were identified as 
AG-targeted agents. 
 
Figure 3.1. Chemical structures of NIR fluorophores 24c and 26e. LogD was calculated using 
MarvinSketch (ChemAxon) 
  
Because these dyes are hydrophobic (logD 6.49 and 6.78) and need to be dissolved in 
aqueous media to be useful for in vivo studies, their solubility and optical properties were 
studied in different solvents. As shown in Table 3.1 both 24c and 26e are most soluble in 
dimethyl sulfoxide (DMSO) with solubility greater than 25 mg/mL and almost completely 
insoluble in PBS buffer. They are also both slightly soluble in fetal bovine serum (FBS). 
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Table 3.1. Solubility and optical properties of compounds 24c and 26e in PBS, FBS, MeOH, and 
DMSO 
 
The absorbance spectra in these solvents can be seen in Figure 3.2. The dyes have the highest 
molar absorptivity in methanol followed by DMSO. The lowest molar absorptivity is seen in 
PBS due to their insolubility in the solvent. As shown in Figure 3.2B, with as little as 1% 
DMSO in saline almost no aggregation is seen and the dyes are completely dissolved. The 
continued increase in molar absorptivity with increased DMSO concentration is due to the 
higher molar absorptivity seen in DMSO compared to saline. 
 
Figure 3.2. Absorbance spectra of compounds 24c and 26e in various solvents. (A) Absorbance 
spectra in PBS, FBS, DMSO and MeOH. (B) Solubility in saline-DMSO mixtures. 5 mM stock 
solutions were prepared in DMSO and added to saline containing 10% FBS 
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The chemical structures and optical properties in neutral buffered serum of all NIR 
fluorophores used in this study are shown in Figure 3.3. MB and 24c exhibited fluorescence 
properties compatible with the 700 nm NIR fluorescence channel of the FLARE imaging 
system while ICG and 26e exhibited fluorescence properties compatible with its 800 nm NIR 
fluorescence channel. In FBS, the synthesized fluorophores had higher molar absorptivity than 
the commercially available dyes with 179,000 M-1cm-1 for 24c compared to 71,200 M-1cm-1 
for MB and 135,000 M-1cm-1 for 26e compared to M-1cm-1 121,000 for ICG. The synthesized 
compounds had higher quantum yields as well. MB had the lowest extinction coefficient and 
QY of all, consistent with prior reports.38 Molecular brightness is generally a better indicator 
of utility in imaging applications because it takes into account both the amount of photons 
absorbed and the ratio of photons emitted compared to those absorbed. The synthesized 
compounds had higher molecular brightness than their counterparts with 24c at 28,282 M-1cm-
1 and 26e at 14,580 M-1cm-1. MB displays a significantly lower molecular brightness than all 
of the cyanine dyes at 2,706 M-1cm-1. 
 
Figure 3.3. Optical properties of NIR fluorophores in FBS, pH 7.4., 3D structures and 
representative absorbance (Abs) and fluorescence (FL) spectra of each fluorophore in 100% 
FBS supplemented with 50 mM HEPES, pH 7.4. 
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3.1.2 In Vivo Imaging 
Despite the improved optical properties, both 24c and 26e have poor water solubility 
because of high logD. To improve the solubility, the dyes were dissolved in DMSO (5 mM), 
and diluted into saline containing 10% serum proteins to a final concentration of 200 µM, 
where both fluorophores were completely dissolved without any precipitates (Figure 3.1). As 
shown in Figure 3.4, 24c and 26e resulted in significant signal intensity in the AGs (SBR > 2.0 
relative to muscle and SBR ≈ 1.5 relative to kidney), which was much higher and more 
sustained than either MB or ICG. However, in mice, background tissue uptake in the liver of 
all four NIR fluorophores was high, resulting in some cases of an SBR < 1.0. Based on the 
kinetics of AG uptake, 60 min post-injection was selected as the optimal time point in mice 
and used for dose ranging.  
 
Figure 3.4. Kinetics of AG signal relative to surrounding tissues and organs. SBR of AG 
compared to surrounding major tissue/organs was measured after 10 nmol intravenous 
injection of each fluorophore 
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As shown in Figure 3.5, there was little dose dependency on either MB or ICG uptake 
in the AG. On the other hand, 24c and 26e showed a dose-dependent uptake in AGs, and 26e 
reached the maximum SBR (AG/Mu) > 4.0 when 50 nmol of each compound was injected 
intravenously in CD-1 mice. A significant difference in the SBR (AG/Mu) was found for 
injected doses 10 nmol for both 24c and 26e. 
 
Figure 3.5. Dose dependence of AG signal. 2-50 nmol of NIR fluorophores were injected 
intravenously 1 h prior to quantitation of SBR. 
 
Based on these kinetic and dose ranging studies, intraoperative imaging of AGs (Figure 3.6) 
was performed at 60 min post-injection of a dose of 10 nmol of contrast agent and resulted in 
distinct highlighting of the glands, and easy differentiation from surrounding muscle and fat, 
and even kidney in mice. 
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Figure 3.6. Intraoperative NIR imaging of AG and surrounding organs (10 nmol at 1 h). 
Bl, bladder; Ki, kidney; Li, liver; Sp, spleen. Scale bars = 0.5 cm. Red pseudo-color was used for 
700 nm and lime green for 800 nm NIR in the merged image. 
 
After resection of the AGs, NIR fluorescence microscopy revealed that both 24c and 
26e showed significant uptake in adrenal cortex, particularly in the zona fasciculate (Figure 
3.7). The fact that these molecules target the adrenal cortex specifically over the adrenal 
medulla suggests that they might share structural similarity to precursor molecules used in 
hormone production in the adrenal cortex, although this hypothesis remains unproven at 
present. 
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Figure 3.7 NIR fluorescence microscopy of adrenal glands resected from animals shown 
in Figure 3.5. Red pseudo-color was used for 700 nm and lime green for 800 nm NIR in the 
merged image. C, cortex; M, medulla; ZF, zona fasciculate. Scale bars = 50 µm. 
 
Because the mouse adrenal gland is so thin (~2.5 mm) and the penetration of NIR light 
can be almost 1 cm, the mouse model actually shows a lower SBR than what we would expect 
to see in humans. To confirm NIR fluorophore kinetics in a large animal model system 
approaching the size of humans, the fluorophores were injected intravenously into 35 kg 
Yorkshire pigs and signal intensity of the AGs and surrounding tissues and organs was 
measured over time. MB was not able to generate a SBR > 1.0 at any time point. ICG generated 
a measurable SBR relative to muscle, but not relative to kidney or liver. As shown in Figure 
3.8, both 24c and 26e, however, resulted in a significant SBR relative to all nearby tissues and 
for an extended period of time. In fact, 26e generated an SBR ≥ 3.0 for 4 hours post-injection. 
No changes in vital signs were observed over the 4 hours experiment. 
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Figure 3.8. Kinetics and intraoperative imaging with 2 µmol intravenous injection of each NIR 
fluorophore in pigs (n = 3): A) Kinetics of AG signal relative to surrounding tissues and organs. 
SBR of AG compared to surrounding major tissue/organs was measured at indicated time 
points up to 4 h. Red pseudo-color was used for 700 nm NIR and lime green for 800 nm NIR in 
the merged image. AG, adrenal gland; Ki, kidney; Li, liver. Scale bar = 3 cm. 
 
Both 24c and 26e appear to perform well for identifying normal AGs across species. At 
first glance, performance of these molecules in mice appears to be lower than that in pig. 
However, the lower SBR in mice is likely the result of the thin diameter of the mouse AG. AGs 
in mice are so thin (~ 1 mm), and the penetration of NIR light so deep (> 5 mm) that thick 
organs like the kidney and liver appear much brighter than they are on a per gram basis. In pig 
and human, however, the AG signal is a true reflection of the relative difference in fluorophore 
uptake among the various tissues and organs. Because of rapid uptake of both fluorophores in 
AGs (within 5 min), injections can be repeated intraoperatively, if needed, to keep the signal 
strong throughout the surgical procedure. What is not known, though, is how they will perform 
in the setting of adrenal tumors. Tumors in the medulla are less likely to exhibit high uptake 
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based on our histological data. Tumors of the adrenal cortex may exhibit high uptake, in which 
case these NIR fluorophores could be used to find local and distant metastases. Given the small 
sample size and complexity of mouse models in these diseases,82 and the fact that tissue path 
length (see above) will confound results, a clinical trial of patients with adrenocortical 
malignancies may be the most efficient way of evaluating the utility of these agents in tumor 
resection. Another concern is the potential toxicity. Although a wide range of doses (2-50 
nmol) has been tested with a clinically compatible formulation (e.g., 10% serum-containing 
saline), neither adverse reactions nor in vivo toxicity were observed. This may be because both 
agents neither cross blood-brain barrier nor accumulate into the reproductive organs in mice 
and pigs (data not shown). It is also well-known that ICG containing the same polymethine 
backbone with 24c and 26e has shown only limited adverse reactions in the clinical use.83 
Finally, 24c and 26e were chosen for use with the two (700 nm and 800 nm) 
independent NIR fluorescence channels of the FLARE imaging system. This, in turn, enables 
mixing and matching of any number of NIR fluorophores for complex surgical procedures. For 
example, 26e (800 nm emission) could be used to highlight the AGs in conjunction with a 700 
nm NIR fluorophore, such as bolus injection of MB, which highlights blood vessels.39 Thus, 
one channel of FLARE could be used to either find or resect (depending on intention) the AGs 
while the other channel is used to quickly find feeding arteries. Similarly, 24c (700 nm 
emission) could be used to find AGs while ICG (800 nm emission) is used to find feeding 
vessels. Similarly, 26e could be used in conjunction with T700-F (700 nm emission to readily 
image the pancreas and adrenal glands allowing the pancreas to be distinguished from the 
adrenal gland rather easily as seen in Figure 3.9.58  
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Figure 3.9. Simultaneous Dual Channel Imaging of Pancreas and Adrenal Gland 2.5 µmol of 
T700-F was injected intravenously for pancreas imaging 4 h prior to adrenal gland imaging 
with 2 µmol intravenous injection of 26e 30 min prior to imaging (n = 3 pigs). Shown are color 
image, 700 nm NIR fluorescence, 800 nm NIR fluorescence, and a merged image of the three. 
For the merged image, FLARE™ channel #1 (700 nm) is pseudo-colored in red and channel #2 
(800 nm) in green. Abbreviations used are: AG, adrenal gland; In, intestine; Pa, pancreas. 
Arrowheads indicate tiny branch from adrenal gland. Scale bars = 1 cm. All NIR fluorescence 
images have identical exposure times and normalizations. 
 
3.2 Parathyroid Gland Targeting 
An initial screen of a NIR fluorophore library containing ~100 novel compounds, 
injected IV into CD-1 mice identified a single potential pharmacophore 26a for parathyroid 
uptake at an emission of 800 nm. The parathyroid glands are four tiny glands, about the size of 
a grain of rice, located behind the thyroid gland which produce parathyroid hormones (PTH) 
that regulate the level of calcium in the blood. Calcium is the primary element that causes 
muscle contraction. PTH must be kept within a narrow window. If too much PTH is released 
hyperparathyroidism occurs. If too little PTH is released hypoparathyroidism occurs leading to 
hypocalcemia and increased levels of blood phosphorus (hyperphosphatemia).84 This is a rare 
condition and most commonly occurs due to damage or removal of parathyroid glands during 
surgery. 
These glands are of considerable clinical importance, yet they are difficult to locate 
during surgery.85 Particularly, a partial or complete resection of the thyroid gland requires 
accurate identification and preservation of the parathyroid glands. In addition, complications 
can occur when all functional parathyroid glands are accidentally damaged or removed during 
thyroidectomies or when they are not completely removed during parathyroidectomies.86,87 
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Using the naked eye, the visualization of normal parathyroid glands and accessory 
thyroid tissue is problematic in high-risk procedures such as those required for central neck 
surgery, thyroid cancer or Graves disease.87,88 Not only are the tissues tiny, but their location 
varies widely from person to person. Because of this microscopy is required to dependably tell 
the difference between parathyroid tissue, thyroid tissues and surrounding lymph nodes.88 
Currently, the only agent known to target glands in the head and neck is MB,89,90 which exhibits 
uptake in a parathyroid tumor (adenoma), but not in normal parathyroid glands. MB fluoresces 
at 690 nm so there are no known fluorophores to target the parathyroid glands in the 800 nm 
region. Surgeons are currently required to rely on visual identification and of the different 
tissues and their experience which can be subjective and inconclusive.91 NIR fluorophores that 
exhibit structure-inherent specific uptake in the parathyroid glands could provide surgeons with 
unmistakable guidance during head and neck surgery after a simple IV injection. 
3.2.1 Optical and Physicochemical Properties 
Based on the pharmacophore of structure of 26a, the initial hit identified during 
screening, a series of fluorophores was designed and synthesized following the same procedure 
in Equation 12 to optimize paraythyroid gland uptake. The NIR fluorophores, shown in Figure 
3.10, emitting at 800 nm were composed of heptamethine cores and decorated with various 
side chains including hydrogen, methoxy, and fluoro groups. The physicochemical and optical  
 
Figure 3.10. Structures of fluorophores for parathyroid gland targeting 
 
properties of these fluorophores are shown in Table 3.2. In order to systematically alter 
hydrophilicity, hydrophobicity, polarity and electron resonance the heterocyclic substituents of 
the polymethine core were altered without changing the nonresonant side chains. All three 
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fluorophores had molecular weights between 400 and 470 and logD between 3.7 and 4.4 
making them relatively hydrophobic compounds. All targeted fluorophores exhibited 
maximum fluorescence in the NIR region and high molecular brightness which together 
minimize tissue autofluorescence and maximize fluorescence signal. Dye 26l had the lowest 
molecular brightness at 8,036 M−1cm−1 due to the electron donating nature of the methoxy 
group donating electrons back into the system.92 The fluorine substitution slightly raised the 
quantum yield to almost 19% giving it the highest molecular brightness at 20,790 M−1cm−1. 
Table 3.2. Physicochemical and optical properties of compounds 26a, 26l, and T800-F in 100% 
serum, pH 7.4. In silico calculations of logD at pH 7.4 and total polar surface area were 
calculated using Marvin and JChem calculator plug-ins (ChemAxon) 
  
26a 26l T800-F 
Molecular weight 409.59 469.64 445.57 
logD at pH 7.4 4.08 3.77 4.37 
Total polar surface area (Å2) 6.25 24.71 6.25 
Extinction coefficient (M−1cm−1) 115,000 98,000 110,000 
Absorbance maximum (nm) 758 785 758 
Emission maximum (nm) 770 804 771 
Stokes shift (nm) 12 19 13 
Quantum yield (%) 15.8 8.2 18.9 
Molecular brightness (M−1cm−1) 18,170 8,036 20,790 
 
3.2.2 In Vivo Imaging in Mice 
As a preliminary in vivo test for thyroid targeting, the NIR fluorophores were IV 
injected into CD-1 mice and imaged at 1 and 4 h. T800-F showed the highest signal-to-
background ratio (SBR) values compared to other molecules. Signal intensity of the thyroid 
tissue in mice decreased only 17% between 1 and 4 hours post-injection. All three fluorophores 
had SBR greater than 1.5 after 1 h, but the SBR from T800-F was greater than 6 after 1 hour 
and sustained above 4 for over 4 hours (Figure 3.11). 
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Figure 3.11. Preliminary thyroid targeting in CD-1 mice. All NIR images have identical 
exposure time. SG, salivary glands; TG, thyroid glands (arrows). 
 
Because T800-F showed the highest SBR, it was chosen for further studies. As shown 
in Figure 3.12, the optimal dose for parathyroid imaging was determined by IV injecting doses 
ranging from 25-100 nmol into mice and the SBR was measured over time. The optimal single 
IV injection dose for CD-1 mice was determined to be 50 nmol (1 mg/kg). T800-F displayed 
clearance through both the liver and kidneys 4 hours after injection, however the fluorescent 
absolute amounts of dye excreted into the urine and feces were difficult to detect. 
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Figure 3.12. Dose dependence of TG signal. 25-100 nmol T800-F was injected intravenously 1 h 
prior to quantitation of SBR 
3.2.3 In Vivo Parathyroid Imaging in Pigs 
Pigs were used as a large animal model for parathyroid identification because they 
represent a worst-case scenario. Unlike in humans, pig parathyroid glands are located in the 
thorax, distant from the thyroid glands and without anatomical markers.93 Thus, it is more 
challenging to differentiate pig parathyroid glands with the naked eye because of their small 
size (a few mm) and location embedded within the surrounding thymus. T800-F was IV 
injected into Yorkshire pigs at a dose of 5 μmol and imaged over a period of 5 h. The 
parathyroid was able to be identified with high sensitivity and specificity with SBR greater 
than 6 after 1 hour and SBR sustained above 4 for over 4 hours post injection. Higher 
fluorescence was seen in the pig parathyroid than in the thyroid 1 hour post-injection and this 
signal was maintained for over 5 h. This can be seen in the parathyroid signal to thyroid signal 
ratio curve (PTR) which reaches a maximum at 3 hours post injection (Figure 3.13). Due to 
this high PTR, T800-F could be used for specific identification of the parathyroid glands. 
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Figure 3.13. In vivo parathyroid and thyroid imaging with T800-F in pigs. Shown are the 
parathyroid and thyroid glands at 1 h and 4 h post injection and a magnified image of the 
parathyroid gland. La, larynx; PG, parathyroid gland (arrowhead); TG, thyroid gland (arrow) 
3.2.4 Simultaneous in vivo NIR imaging of parathyroid and thyroid 
The dual-NIR channel capability of the FLARE imaging system was exploited to 
provide surgeons with clear-cut markers during head and neck surgery. Rats were initially 
chosen as they possess a single pair of parathyroid glands located on the anterior and lateral 
aspects of the thyroid lobes.94 For dual-channel imaging of the glands, T800-F was injected 
concurrently with a dye previously synthesized by our lab that targets the thyroid gland and 
fluoresces at 700 nm, T700-F. T800-F was IV injected into a 250 g Sprague-Dawley (SD) rat 
2 hours before imaging followed by T700-F injected into the same animal 6 hours before 
imaging. These are the optimal doses and timing determined during initial screening tests. 
Under these conditions T800-F allows for the parathyroid to be visualized unmistakably and 
T700-F simultaneously highlights both glands. The tissues were resected to confirm their 
identities by NIR fluorescence microscopy and consecutive H&E staining. As predicted, T700-
F was observed in both thyroid and parathyroid glands, whereas T800-F remained only in the 
parathyroid gland. To confirm that these results are independent of species, the experiment was 
repeated in the pig model (Fig 3.14). T800-F was determined to target the chief and oxyphil 
cells of the pig parathyroid. 
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Figure 3.14. Dual channel NIR imaging in pigs using both T700-F and T800-F. T800-F was IV 
injected 4 h before imaging followed by T700-F 2 h later. La, Larynx; PG, parathyroid glands 
(arrowheads); TG, thyroid gland (arrows). Pseudocolored red and green colors were used for 
700-nm and 800-nm channel images, respectively, in the color-NIR merged image. Scale bars, 
300 μm. All NIR fluorescence images have identical exposure and normalizations. 
 
The mechanism of uptake and retention of T800-F in specific cell types of the 
parathyroid glands is presently unknown. It seems that site-specific halogenation on the 
heterocyclic moiety of the cyanine dye is critical for targeting and it is possible that these 
molecules are being mistaken by iodine-processing cellular machinery (such as transporters 
and enzymes) as endogenous substrates. Future studies could focus on the identification of the 
intracellular targets of these contrast agents; however, it should be noted that contrast agent 
optimization can continue even when only the target cell type and preliminary pharmacophore 
are known. 
The ability to identify the thyroid and parathyroid glands simultaneously after simple 
IV injection using the dual-NIR channel capability of the FLARE imaging system advances 
the potential for head and neck surgery to be performed with better precision and thus fewer 
surgical accidents and lower mortality. This study also provides design considerations for 
developing disease-specific contrast agents utilizing a structure inherent targeting strategy. 
Discovering these agents is an arduous process. In the case of the adrenal and 
parathyroid glands, it required the synthesis and screening of a large NIR fluorophore library 
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of ~300 compounds before optimization of the presumed pharmacophore. The strategy can be 
applied to almost any desired target and as the library continues to increase in size, 
pharmacophores for any particular target become more available.95,96 
3.3 Cartilage Targeting 
Sections 3.1 and 3.2 have shown that structure inherent targeting can be discovered 
through screening libraries of compounds, but it is important to note that structure inherent 
targeting can also be achieved by introducing targeting groups into the nonresonant structure 
of the fluorophore. For example, phosphonate derivatives have been widely used for targeting 
bone due to their high affinity for minerals and calcium salts found in bone surfaces.97 In this 
section the development of a cartilage specific fluorophore based on this type of rationale 
design is discussed.  
Healthy cartilage is an essential component to a good quality of life. The functions of 
cartilage include cushioning joints and intervertebral spaces, giving the ears and nose form, 
and protection of the trachea. All three histological types of cartilage are produced by 
chondrocytes, or more precisely chondroblasts, until they are trapped within their own cellular 
matrix.98-100 The types of cartilage differ mainly in the relative amounts of collagen, 
proteoglycans, and elastin they contain. 
Cartilage dysfunction leads to several acute and chronic indispositions. In degenerative 
joint disease (DJD, osteoarthritis), destruction of cartilage on the articular surfaces of joints 
leads to pain and debilitation. DJD affects 27 million patients in the US alone and results in 
huge economic losses.101 Unlike bone, cartilage does not have the ability to regenerate. 
Replacement therapies through tissue engineering and pharmacological treatment that prevent 
destruction are being intensely researched. However, even if these therapies were available 
currently, there would be no way to evaluate these treatments noninvasively or to guide surgery 
for neo-cartilage transplantation. 
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Despite its importance, cartilage is difficult to image. Most efforts to image and 
quantify cartilage have focused on magnetic resonance imaging (MRI)98,102 however, cartilage 
is a poor target for MRI  due to its water-deficient composition.103 It is also a poor target for 
clinical computer tomography (CT) due to low X-ray absorption, and when using conventional 
microCT, it is essentially invisible.104 A SPECT radiotracer for cartilage was reported in 
2001,105 but recent preclinical study literature shows poor image quality106 and clinical studies 
have not followed. To date, there is not a single optical contrast agent for cartilage and certainly 
not one in the NIR range.  
In the 1970s improved isolation and chromatographic procedures allowed for the 
purification and analysis of tissue proteoglycans and glycosaminoglycans (GAGs). The 
separation of the large aggregating proteoglycans from cartilage left a complex proteoglycan, 
hyaluronan, and link protein. These GAGs consist of repeating disaccharide units composed of 
N-sulfated hexosamine. This high density of negative charges allow cartilage to retain a large 
amount of water and be surrounded by cations that form the gel in the extracellular matrix of 
cartilage;100 therefore, it was hypothesized that the introduction of cationic groups on a 
fluorophore should allow it to interact with anionic cartilage tissue. A proposed tricationic 
pharmacophore for NIR cartilage targeting can be seen in Figure 3.15.  
 
Figure 3.15. Proposed pharmacophore for high-specificity cartilage binding in vivo. 
 
3.3.1 Physicochemical and Optical Properties 
The physicochemical and optical properties of the proposed pharmacophore with 
modifications to the heterocycle are summarized in Table 3.3. The hydrophobicity, polarity, 
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and electron-resonance properties of the final NIR fluorophores could be systematically altered 
without affecting the emission wavelength by modifying the nonresonant substituents on the 
heterocycles as shown in the structures in Figure 3.16. The modifications included a methoxy 
group as an example of an electron donating substitution, an additional benzene on the 
heterocycle for increased hydrophobicity, and a sulfonate group making the net charge +1. All 
four compounds had similar optical properties with emission ranging from 788-818 nm and 
molar absorptivities from 101,500 M-1cm-1 to 179,000 M-1cm-1. The compound with the 
benz[e]indole heterocycle had the highest molecular brightness, followed by the methoxy and 
sulfate substituted compounds. 
Table 3.3 Physicochemical and optical properties of NIR fluorophores 26h-k. Theoretical 
calculations of the molecular properties were calculated by using Marvin and JChem calculator 
plugins. All optical measurements were performed at 37 °C in 100% FBS buffered 
with 50 mm HEPES, pH 7.4. 
 
 
Figure 3.16 Structures of tricationic NIR fluorophores 26h-k 
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3.3.2 In vivo imaging 
As a preliminary test for cartilage targeting in vivo, the NIR fluorophores were 
intravenously injected into CD-1 mice. After 4 hours the mice were imaged and the fluorescent 
signals in the costal cartilage tissues were quantified (Figure 3.17). 
 
Figure 3.17. In vivo cartilage targeting with in mice. Each fluorophore was injected 
intravenously into CD-1 mice 4 h prior to imaging. The SBR (Ca/Mu) was calculated from the 
fluorescence intensity of costal cartilage tissues versus the signal intensity of neighboring muscle 
obtained over the imaging period. All NIR fluorescence images have identical exposure and 
normalization. Scale bars=1 cm. 
 
As expected, the sulfonated control compound 26k with a net charge of +1 showed no 
cartilage uptake. This compound had increased hydrophobicity compared to the others (logD 
at pH 7.4 of -1.67) and the negatively charged sulfonates could cause repulsion from the anionic 
GAGs. In addition, the polarity value for 26k is near 120 Å2, which generally is outside the 
range of values where good cell membrane permeability would be expected.107 While the dye 
26j showed cartilage uptake, its increased hydrophobicity and unbalanced 3D conformation, 
due to the benz[e]indole heterocycle, caused high nonspecific background signals. 
Interestingly, the methoxy substituted compound 26i exhibited the highest SBR (calculated 
from the difference in fluorescence intensity between costal cartilage and neighboring muscle) 
values compared to the other molecules, and 26h also showed high cartilage uptake. Although 
the synergistic effects of the methoxy groups on the cationic polymethine structure for efficient 
cartilage binding are not well understood, the addition of methoxy groups improved the 
hydrophilicity (LogD at pH 7.4 < -4.0) and increased the polar surface area (24.71 Å2). 
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Because 26i showed the highest SBR for cartilage tissues among the different 
compounds tested, the methoxy-substituted NIR fluorophore was selected for further in vivo 
studies. All major cartilage tissues were imaged 4 hours post injection with 26i in CD-1 mice 
to determine whether cartilage type (hyaline, elastic, or fibrocartilage) had an effect on uptake. 
After a single intravenous injection of 26i, all cartilage tissues were clearly visualized, 
including ears/nose, knee joints, costal cartilages, and intervertebral discs. 
 
Figure 3.18. In vivo NIR imaging of cartilage tissues from ear, knee joint, and thoracic cavity in 
mice. Dye 26i was intravenously injected into 25 g CD-1 mice 4 h prior to imaging. The arrows 
in the knee joint indicate the growth plates. The white arrows labeled 1 and the white 
arrowheads labeled 2 in the chest cavity indicate hyaline and fibrocartilage, respectively. NIR 
images of resected cartilage tissues were obtained from the same animal. All NIR fluorescence 
images for each condition have identical exposure times and normalizations. Scale bars=1 cm. 
 
Because the composition of each cartilage tissue is different, histological evaluations 
with Alcian blue and hematoxylin and eosin (H&E) staining were performed. Alcian blue (dark 
blue staining) mainly stained acidic GAGs in cartilage, where strong NIR fluorescence was 
also observed. The histology data also confirm binding to all three types of cartilage. Since 
cartilage tissues are all produced by chondrocytes (or more precisely chondroblasts) and differ 
mainly in the relative amounts of collagen, proteoglycans, and elastin present, these NIR 
fluorophores are most likely binding either to the surface of chondrocytes, or more likely, to a 
secreted molecule with a high local concentration. Interestingly, the growth (epiphyseal) plate 
which is composed largely of hyaline cartilage was also targeted along with the fibrocartilage 
of the knee joint in the young mice (8 weeks) used for the study suggesting that these NIR 
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fluorophores could even bind cartilage in early developmental stages because the growth plate 
is generally only found in children and adolescents. 
3.3.3 Simultaneous in vivo NIR imaging of cartilage and bone 
Lastly, the dual-channel capability of the FLARE imaging system was utilized to 
highlight cartilage and bone tissues simultaneously in real time.  The combination of cartilage 
targeting and bone targeting was tested by injecting 26i with a bone targeting agent previously 
synthesized by our group108 P700-SO3 together into mice and pigs. Cartilage and bone tissues 
were easily identifiable by different channels of the FLARE system as shown in Figure 3.19. 
This method could prove to be useful in future tissue engineering studies, in which transplanted 
neocartilage could be visualized in one NIR channel and either bone or blood vessels could be 
visualized in the other. During human surgery, these new imaging agents might prove useful 
for assessing cartilage thickness during arthroscopy, or for finding discreet damage to joints. 
 
Figure 3.19. Dual-channel in vivo fluorescence imaging of cartilage and bone tissues in the same 
animal.  
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3.4 Conclusion 
Along with pancreas-specific58 and bone-specific NIR fluorophores,97 these novel 
specific NIR fluorophores described herein are examples of “structure inherent targeting”, in 
which tissue-/organ-specific targeting is engineered directly into the nonresonant structure of 
a NIR fluorophore. The incorporation of tissue-targeting moieties into the chemical structure 
of the contrast agent creates a bifunctional molecule eliminating the need for conjugation of 
targeting and fluorophore domains and thereby enabling subsequent optimization of in vivo 
properties including biodistribution, clearance, and elimination. As the number of NIR 
fluorophores developed with specific targets increases, the combinations that can be used 
together increase significantly, as do the amount of complex surgical procedures that can 
benefit from the technology. It is hoped that the present findings will lay the foundation for 
improved diagnosis and treatment of diseases. 
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4 STEM CELL TRACKING  
4.1 Introduction 
Longitudinal tracking of live cells in living organisms is crucial to understand the 
function, toxicity and therapeutic mechanism of systemically or implanted stem cells in clinical 
use.109 Currently, it is difficult to find the localized and differentiated cells after extracting the 
tissue construct from the body (i.e., histological analysis).110 The ability to monitor localization 
and behavior of administered cells for extended periods of time using high-resolution in vivo 
optical imaging techniques would provide critical information in the treatment of diseases. To 
identify administered cells from the host tissue for real-time in vivo analysis and ex vivo post-
analysis, the target cells must be labeled with a nontoxic and stable imaging probe that can 
retain its fluorescence in a biological environment long enough to be tracked.111 General 
strategies to track cells using contrast agents for optical imaging include endogenous 
biomolecule tracers112 and fluorescent proteins,113,114 however, these suffer from photo-
bleaching, leakage of tracers, and engulfment by nearby cells resulting in false-positives.115,116 
In order to overcome these limitations, exogenous functional molecules, especially NIR 
fluorophores, have been developed for staining cellular components.107,117 Optical fluorescence 
imaging has the potential to solve these problems, but two fundamental problems remain. 
Long-term in vivo tracking is difficult due to the chemical and metabolic degradation of 
fluorophores118 and even agents retained in cells are washed out or destroyed during 
histopathological tissue processing.119 
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Figure 4.1 Known agents for cell staining 
 
To solve these fundamental problems, many subcellular components and organelles, 
such as DNA, lysosome, endoplasmic reticulum (ER), Golgi complex and mitochondria, have 
been targeted.120,121 Several functionalization strategies have been developed to design such 
imaging probes with high affinity to selective organelles. For example, hydrogen peroxide-
targeted and pH-sensitive fluorophores, such as Cy-O-SeH (Figure 4.1) rapidly target 
lysosomes and mitochondria; however, due to their photo- and physicochemical instability 
long-term monitoring has not been achieved.122,123 Genetically encoded tagging to the 
membrane proteins and DNA with compounds such as firefly luciferase (FLuc, Figure 4.1) is 
generally more stable, but requires multiple replications and can be difficult to reach the 
fluorescence density required for imaging cells in a short period of time.124,125 Current focus 
has fixated on the development of optical probes targeting membrane organelles such as ER, 
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mitochondria (Mitotracker Orange, Figure 4.1) and lysosome (Lysotracker Red, Figure 4.1) to 
trap the probes inside the membrane by chemical alteration using membrane potential, proteins, 
and fixatives to eliminate efflux and washout after destruction. However, most of these agents 
are in the visible range (400-650 nm) and only a few are available in the NIR wavelength.126  
4.2 Rationale 
The major challenges of fluorescence imaging for in vivo cell tracking are insufficient 
photostability and cytoxicity, which limit imaging to fixed cells without continuous recording 
of the fate of cells in real time after administration of stained cells. An innovative design of 
fluorophores with two functional domains allows for avoidance of physical or biochemical 
interference of fluorophores to the cellular activities by inducing rapid passive diffusion into 
the cell followed by selective lysosomal sequestration and then trapping the fluorophores inside 
the cells. In addition, the fixable property of fluorophores allows for retaining in the tissue after 
resection and chemical treatment for histological analysis.  
 
 
 
Figure 4.2. Chemical structures of 45, 32 and IR786 
 
59 
 
The two main functional domains the NIR probe was designed to contain were a 
lipophilic imaging core and an ionizable docking chain as shown in Figure 4.2. The imaging 
domain uses a heptamethine cyanine core, which emits at 790 nm with high photostability.73,127 
Sufficient photostability is an essential property for prolonged live cell imaging. Additionally, 
this imaging core provides appropriate lipophilicity (LogD >1.0 at pH 7.4) allowing the 
fluorophore to penetrate inside the live cell membrane. As illustrated in Figure 4.3, the rationale 
is to introduce a primary amine that, once inside the acidic environment of the lysosome, will 
undergo a shift in equilibrium between charged and uncharged favoring the ionized form that 
could limit the diffusion of 45 back across the lysosomal membrane into the cytosolic space.128 
As a result, the protonated 45 will be retained inside the cell, which is of importance to be an 
inert cell tracer with enhanced photo-activity.129 
  
Figure 4.3 Lysosomal sequestration of 45 
 
How suitable an optical probe is for in vivo live cell imaging is dependent on the 
different ionizable docking functional groups attached to the heptamethine cyanine imaging 
core. To compare selective cellular retention and further docking in the subcellular component, 
the meso-carbon position of the heptamethine was functionalized with a primary amine for 45 
and a carboxylic acid for 32. The commercially available heptamethine IR786 containing an 
unmodified chloride on the fixable group was used as a control. 
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Table 4.1 Physicochemical properties of lipophilic NIR fluorescent fluorophores 45, IR786 and 
32 
Physicochemical property 45 IR786 32 
Formula C42H50N3O C32H36ClN2 C41H45N2O3 
Molecular weight (Da) 612.87 484.09 613.81 
LogD at pH 7.4 3.5 4.79 6.54 
Total charges at pH 7.4 1 1 0 
pKa, strongest basic 9.81 1.92 4.05 
Topological polar surface area (Å2) 41.5 6.25 52.78 
Hydrogen bond acceptor(s) 3 1 7 
Hydrogen bond donor(s) 1 0 1 
 
The physicochemical properties of the NIR fluorophores used in this study are 
summarized in Table 4.1. All three probes are lipophilic cations (logD >3.0 at pH 7.4) which 
can readily diffuse across the cell membrane by passive diffusion, but only 45 becomes 
protonated (pKa >6.0) in the acidic environment of lysosome (pH 4-5).
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4.3 Results and Discussion 
4.3.1 Synthesis  
 
Scheme 4.1 Synthesis of amine containing heptamethine cyanine 
 
As described in Chapter 2, chloro substituted dyes were synthesized through salt 
condensation with Vilsmeier-Haack reagent to build the heptamethine cyanine core. This dye 
was then functionalized by reaction of the meso chlorine atom of 27k with the appropriate 
nucleophile through the SRN1 displacement pathway as described in Scheme 4.1. Tyramine 
hydrochloride 43 was first Boc protected to form compound 44 and ensure selective reactivity 
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at the oxygen atom. The Boc protected product is then converted to the free amine by treatment 
with trifluoroacetic acid (TFA) in dichloromethane at 0 °C to yield dye 45 which was purified 
by flash column chromatography. The synthesis of dye 32 was described in Section 2.10. 
4.4 Optical Properties 
Comparative absorption and fluorescence emission spectra were recorded for three 
fluorophores and all three probes had similar emission at 790-800 nm as shown in Figure 4.4. 
 
Figure 4.4. Comparative absorption and fluorescence emission spectra of 42, IR786 and 32 
 
The optical properties of the NIR fluorophores used in this study are summarized in Table 4.2. 
Extinction coefficient and fluorescence quantum yield values for 45 and 32 in serum-
containing media were similar with extinction coefficients ~150,000 M-1cm-1 and quantum 
yields of 29% owing to molecular brightness of 44,660 M-1cm-1 and 39,825 M-1cm-1, 
respectively. These values are significantly higher than the commercially available IR786 
which has an extinction coefficient of 117,500 M-1cm-1 and quantum yield of 23% owing to its 
molecular brightness of 27,025 M-1cm-1. 
Table 4.2. Optical properties of lipophilic NIR fluorescent fluorophores 45, IR786 and 32 
Optical property in media 45 IR786 32 
Absorbance maximum (λabs, nm) 778 786 773 
Emission maximum (λem, nm) 790 800 786 
Stokes shift (nm) 12 14 13 
Extinction coefficient (ε, M-1cm-1) 154,000 117,500 137,500 
Quantum yield at 770 nm (Φ, %) 29.0 23.0 29.0 
Molecular brightness (M-1cm-1) 44,660 27,025 39,825 
 
62 
 
4.4.1 Cell testing 
To compare the cellular permeability and retention, all 3 NIR fluorophores were loaded 
into living PC3 cells individually, and their cellular behaviors were compared at various 
conditions. All 3 lipophilic cations achieved saturation of loading into cells after only 10 min 
with extracellular concentrations ranging from 0.5 to 10 µM. Even at these high concentrations, 
no evidence of toxicity was observed, i.e. there has been no observed change in cellular 
morphology, no decrease or increase in the rate of proliferation, and no change in cell plating 
efficiency. In addition, as shown in Figure 4.5, the strong signal strength of 45 was maintained 
in active proliferation of the cells for over 24 hours after incubation, while cells stained with 
IR786 and 32 had almost no signals after 24 hours due to the efflux of fluorophores. 
 
Figure 4.5 Long-term cellular stability of 45, IR786, and 32 in live PC3 cells 
 
To show that 45 is fixable, the cells were treated with 4% formaldehyde after staining 
and washed with 1% Tween 20 (Figure 4.6). Despite potential interaction of the chloride atom 
of IR786 with intracellular proteins, virtually no intracellular retention was observed after 
fixation and detergent washing. Dye 45, however, is fixed in place with no loss of signal after 
detergent washing. Dye 45 demonstrated high efficiency and rapid loading into live cells, as 
well as exhibited excellent partitioning behavior and retention. 
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Figure 4.6. Cellular stability of 45, IR786, and 32 after formaldehyde fixation and detergent 
washing. Scale bars = 25 µm. 
 
4.4.2 Animal studies 
To validate the cell studies for in vivo cell tracking, PC3 cells stained with either 45 or 
IR786 were suspended in the media solution and intravenously administered into syngeneic 
C57BL/6J mice. The mice were sacrificed at 5 minutes and 24 hours post-injection, and then 
the thoracic cavity was opened and imaged under real-time image guidance using the 
intraoperative optical imaging system (Figure 4.7). Initially, the cells with both 45 and IR786 
showed similar signal intensity from the lung. However, after 24 hours, only the cells in the 
lung stained with 45 could be observed. The signal intensity of the lung was rather attenuated 
at 24 hours due to migration of the cells from the lung capillaries to the liver, which was 
traceable by an increased signal in the liver. 
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Figure 4.7. In vivo tracking of stained cells using the intraoperative optical imaging system. 45 
and IR786-stained cells were trapped in the lung with strong fluorescent signal at 5 min post-
intravenous injection. The cells stained with 45 were found in the liver as an evidence of cell 
migration from the lung capillaries at 24 h post-injection. All NIR fluorescence images are 
identically normalized. Abbreviations used are: He, heart; Li, liver; Lu, lung. Scale bars = 3 
mm. 
 
This in vivo cell tracking was emphasized by changing the injection method. As shown 
in Figure 4.8, cells orthotopically injected into the liver were found in the lung 6 hours post-
injection, which implicates migration of the cells through hepatic vasculatures. NIR in vivo 
fluorescence imaging confirmed that prolonged lysosome sequestration of 45 is the key to real-
time visualization of tracing administered cells. This mechanism differs from other lysosomal 
targeting and pH sensitive probes where their purpose is to monitor cellular trafficking process. 
In this case, probes are effluxed out of the targeted organelle in 1-2 hours. The fixable property 
of 45 is unique from all other subcellular-targeted probes. It has potential for clinical 
translation, especially for cell-based therapy, such as immune cancer therapy and cardiac stem 
cell regeneration which can be solved using 45, where the homing and behavior of cells after 
administration can be monitored and analyzed.  
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Figure 4.8. In vivo tracking of cells stained with 45 injected into the liver using the 
intraoperative optical imaging system. The cells were found in the lung after 6 h, implicating 
liver-to-lung trafficking of the cells. All NIR fluorescence images are identically normalized. 
Abbreviations used are: He, heart; In, intestine; Ki, kidney; Li, liver; Lu, lung. Scale bars = 3 
mm. 
 
Another major problem with the use of cell tracking fluorophores is the inability to fix 
contrast agents intracellularly using formalin or paraformaldehyde. Washout and/or destruction 
of such fluorophores during H&E histological staining is currently a common challenge.131 
H&E is the gold standard for analyzing biopsy specimens from clinical trials, and cell tracking 
technology must be compatible to make a substantial impact in the field.132 However, H&E 
processing is extremely harsh, requiring exposure to organic solvents as strong as xylene, and 
heating to at least 65 °C. Currently there are no fixable NIR fluorophores that can withstand 
these severe conditions. Dye 45 has the ability retain high stability while fixed covalently 
within the cell using formalin or paraformaldehyde. To prove this, the same process used 
clinically on every human tissue biopsy, using the cell pellet and lung tissue was followed with 
45 and IR786.129 The cell pellets underwent the same histological preparation to evaluate the 
fluorescence retention or attenuation. As shown in Figure 4.9a, while IR786 was largely 
washed away during histological processing, 45 was fixed in place and withstood organic 
solvent washing and H&E staining. The lung tissues were harvested after intravenous 
administration of the stained cells, and a cryosection was performed followed by H&E staining. 
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As expected, 45 was resistant to the harsh processing and allowed further visualization of the 
cells (Figure 4.9b). This makes it possible to combine NIR fluorescence and H&E staining of 
the same slide, and thus to locate a single cell on an H&E stained tissue slice while co-staining 
for differentiation markers. 
 
Figure 4.9. Stability of histological processes, including formaldehyde fixation and H&E 
staining. (a) Cell pellets mimicking the tissue structure and (b) the lung tissue sections harvested 
from mice after intravenous administration of the stained cells.  All NIR fluorescence images 
have identical exposure and normalization. Scale bars = 25 µm. 
 
Finally, to confirm the lysosomal sequestration, PC3 cells were stained with 45 and a 
commercially available LysoTracker dye (Figure 4.10). They clearly co-registered each other, 
however, 45 displayed prolonged retention compared with the LysoTracker, although both 
showed similar stability in serum. This proves that 45 is fixable and ionizable inside the 
lysosome limiting efflux elimination and thereby enabling quantitation of cell survival and 
differentiation at the single cell level. 
 
Figure 4.10. Lysosomal sequestration of 45 (left), LysoTracker (middle), and merged image 
(right). Scale bars = 25 µm. 
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4.5 Conclusion 
In this study, a single NIR fluorophore was synthesized to monitor the fate of injected 
cells in vivo and ex vivo using high-resolution optical imaging techniques. Specifically, this 
amino-functionalized fluorophore 45 selectively targets lysosomes and exhibits outstanding 
physicochemical and optical properties in serum as well as in vivo, which enabled longitudinal 
tracking of living cells in the body and even after extraction from the body. The novel cell 
tracking NIR fluorophore 45 survives all steps in H&E histological tissue processing while 
retaining excellent NIR fluorophore properties. The lipophilic cation structure allows for 
cellular membrane permeation, and the primary amine is used for rapid sequestration followed 
by efficient intracellular fixation by formalin through reductive amination. This amine structure 
also reduces the risk of efflux of NIR fluorophores from the cell membrane enabling tracking 
of single cells for determining the mechanism of various diseases in the body. Therefore, 45 
has the potential to be useful in labeling various types of cells to study their in vivo and ex vivo 
fate at the single cell level.  
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5 “Turn on” fluorescence response of monomethine cyanines caused by noncovalent 
binding to ct-DNA 
5.1 Introduction 
Imaging of macromolecules such as DNA by staining with fluorescent compounds is of 
great interest; therefore, expanding the options of available probes is vital to several areas of 
research spanning from medical diagnostics to genomics. The synthesis of low cost, easy to 
manipulate systems for fast analysis is required.133 Fluorescent detection has rapidly become 
one of the most widely used techniques due to its sensitivity and noninvasiveness.70 Ethidium 
bromide has commonly been used for the detection of DNA, however it has mutagenic effects 
and poses other environmental concerns.134-136 On the other hand, cyanine dyes are sensitive, 
safe and highly modifiable.66,69,137 
As described previously by our group, monomethine cyanines possess a valuable 
characteristic of only displaying fluorescence when rotation around the methine bridge is 
restricted.65,66 These dyes are the best non-convalent binding nucleic acid labels due to their 
high binding constants, large molar absorptivities and quantum yields and high fluorescence 
signals upon binding. Two commercially available monomethine cyanines are among the most 
popular intercalating agents and have recently been used for DNA and chromatin imaging with 
super-resolution fluorescence microscopy.138 While there is still much to explore regarding 
what effect structure has on the photophysical properties, our lab has developed ways to 
redshift the monomethine scaffold by altering the terminal heterocycles.65,66 Understanding 
how to redshift the monomethine cyanine dyes allows for the enhancement of existing 
molecular probes minimizing background absorption and fluorescence. While it is well known 
that monomethine cyanines tend to bind DNA139-141 there is a lack of literature on what causes 
or prevents a cyanine from binding to DNA. Herein a series of monomethine cyanines that 
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differ only in one heterocycle were synthesized to investigate how these different heterocycles 
influence DNA binding. 
5.2 Results and Discussion 
5.2.1 Synthesis 
Toward correlating the various heterocyclic moieties and their ability to bind DNA, we 
began to rationally design monomethine cyanines containing the benz[c,d]indole heterocycle 
on one half of the dye. The other side possessed different heterocycles including 2-
methylbenzothiazole, 2-methylbenzoxazole, 2-methylquinoline, or 3,3-dimethylindole, 
heterocycles all with butyl side chains on the nitrogen. As shown in Table 5.1, the 
physicochemical properties of these four compounds are all very similar with molecular weight 
from 397-423 (without counterion) and polarizability from 76-80. They are all hydrophobic 
molecules with LogP between 7 and 10. With the exception of the benzoxazole containing dye 
they have similar topological polar surface area (TPSA). The oxygen atom typically raises the 
TPSA, but there is no way to keep it in line with the other compounds without altering the 
structure drastically. Due to the similarity of their physicochemical properties any change 
observed in binding to DNA should be based on the 3D structure of each dye. 
Table 5.1. Physicochemical properties of monomethine cyanines 46 
 
Dye MW 
(amu) 
LogP TPSA 
(Å2) 
Polarizability 
OX  397.54 7.68 5.479 76.21 
BTZ  413.60 8.25 1.674 77.39 
Q 407.58 8.69 1.165 78.36 
IN  423.62 9.23 1.752 80.37 
 
The asymmetrical red-shifted monomethine cyanine dyes were synthesized as shown 
in Scheme 5.1. The key intermediate 7b which was used as one heterocycle for the 
monomethine cyanines was synthesized as described in Scheme 2.1. The second heterocycle 
included 2-methylbenzothiazole, 2-methylbenzoxazole, 2,3,3-trimethylindole, and 2-
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methylquinoline were alkylated, respectively, with iodobutane various alkyl halides in 
acetonitrile to form quaternary ammonium salts 46. The two heterocycles 7b and 3 were then 
connected by a condensation reaction in acetonitrile with triethylamine to afford final dyes 46.  
 
 
Scheme 5.1. Synthesis of monomethine cyanines 
 
The monomethine reaction begins with the deprotonation of the methyl group at the 2 
position of the heterocycle. This activated methylene group of the various heterocyclic salts 3 
displaces the methyl sulfide moiety of 7b and results in the formation of the monomethine 
dyes. After isolation of the final dyes via precipitation from methanol with diethyl ether, the 
dyes were characterized by HRMS, 1H and 13C NMR and their optical properties were 
investigated. 
5.2.2 Optical Properties 
Table 5.2. Energy values and optical properties of the monomethine cyanines 46 
Dye 
λmax 
(exp.) 
λmax 
(calc.) 
ε 
(M-1cm-1) 
OX 500 490 39,900 
BTZ 560 505 30,700 
Q 585 522 35,900 
IN 559 530 25,200 
 
The optical properties of the monomethine cyanines were measured in ethanol. As 
shown in Table 5.2 the absorption maxima range from 500 nm in the benzoxazole containing 
dye OX to 585 nm with the increased conjugation of the quinoline system in Q. Their molar 
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absorptivities range from 25,000 M-1cm-1 in the dimethylindolenine compound IN to almost 
40,000 M-1cm-1 in the benzoxazole compound OX. Benzoxazole compounds are known to be 
brighter. In general, the molar absorptivities are low for monomethine cyanines due to the 
benz[c,d]indole heterocycle present on the other end of the dye, but it is this heterocycle that 
causes the absorbance to be redshifted about 100 nm from where the dyes would generally 
absorb if they were symmetrical.69 Scientists have attempted to approximate wave functions 
and energies for atoms and ions since the late 1920s.142 Over the past 90 years there has been 
significant improvements for predicting behaviors of these systems and more complex ones. 
The ability to use theoretical calculations to predict optical properties of fluorophores, such as 
monomethine dyes is a useful tool for screening compounds which can eliminate the need to 
synthesize them first thus reducing harmful environmental impact. The ability to use theoretical 
calculations of optical properties for fluorophores, such as monomethine dyes could be useful 
for the development of viscosity detection fluorophores or bioimaging agents with desirable 
optical profiles.66 The dyes were modeled with a restricted dihedral angle to disallow rotation 
around the methine carbon. Their geometries were optimized using Hartree-Fock dynamic 
functional theory (HF-DFT) hybrid exchange-correlation functional and B3LYP/6-31G* basis 
set to predict the energy of the compounds at ground state.143 The experimental results mostly 
agree with the trend of the computationally predicted energy gaps. None of these compounds 
display significant fluorescence unaccompanied in ethanol. 
5.2.3 DNA Binding 
It was previously shown by our lab that only when the monomethine cyanine’s ability 
to rotate around the methine bridge is restricted do the dyes relax by fluorescence.65 The dyes 
generally do not fluoresce in free flowing solvent, but when the rotation around the methine 
bridge is restricted such as in glycerol or when bound, fluorescence can be measured. The 
binding of these dyes to ct-DNA restricts this rotation and allows for the unique “turn-on” 
72 
 
fluorescence of these compounds.66 This property was exploited to determine how strongly 
each heterocycle interacts with DNA compared to the others. Table 5.3 shows the binding 
constants and emission maxima of the monomethine cyanines. 
Table 5.3. Binding constants and λemission of monomethine cyanine dyes 46 with various 
heterocycles 
Dye λemission 
(nm) 
Kb 
(M-1) 
OX  555 1.6 x 104 
BTZ 583 1.1 x 104 
Q 680 1.8 x 102 
IN  686 1.6 x 10-3 
TOα 525 1.7 x 105 
αPublished values λemission144 and Kb145 
 As shown in Figure 5.1, dye OX displayed the greatest increase in fluorescence 
when in the presence of ct-DNA with a 700-fold increase. The dye goes from non-fluorescent 
with no DNA present to almost 700 fluorescence units with 20 μM DNA. This is due to both 
the binding affinity of the dye (1.6 x 104 M-1) and the tendency of benzoxazole to decrease non-
radiative deactivation due to fast intersystem crossing.146 The benzothiazole containing dye 
BTZ shows a similar binding affinity (1.1 x 104 M-1), but less fluorescence with only about a 
40-fold increase. The sulfur atom in benzothiazole can cause the opposite effect of the oxygen 
in benzoxazole due to a lower singlet-triplet energy gap raising the opportunity for non-
radiative relaxation.69 The change in binding affinity is not very significant, but is likely due to 
the larger size of the sulfur atom compared to oxygen. This dye is similar to the commercially 
available dye thiazole orange (TO) which has a binding affinity in the order of 105 M-1.145 TO 
likely has higher affinity due to steric hindrance of the butyl groups in our dyes as well as the 
larger size of the benz[c,d]indolium heterocycle compared to the quinoline in TO. These values 
are also on par with similar monomethine cyanine dyes.133  
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Figure 5.1. Representative fluorescence spectrum of OX and IN at constant dye concentration of 
10 μM with increasing ct-DNA concentrations from 0-20 μM 
 
Unlike the BTZ and OX compounds which showed excellent binding, the IN 
compound containing a 3,3-dimethylindolenine heterocycle showed almost no binding with a 
binding affinity of 1.6 x 10-3 M-1. This compound was 14 orders of magnitude lower than the 
benzothiazole and benzoxazole compounds and any binding it may have shown is likely from 
the benz[c,d]indole heterocycle on the other side of the dye. Because all of the physicochemical 
properties of the dye have been kept similar and the only change is the dimethyl group, it can 
be concluded that the dimethyl groups are perpendicular to the plane of the heterocycle 
providing steric hindrance that prevents this binding. Our group has reported similar properties 
with the 3,3-dimethylindolenine preventing duplex DNA binding but still allowing for binding 
to G-quadruplex DNA in other cyanine classes.147 This can be seen in the 3D electrostatic 
potential maps shown in Figure 5.2. 
 
Figure 5.2. Electrostatic potential maps of monomethine cyanines 46 
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This finding is of utmost importance as the dimethyl functionality can be exploited to 
prevent off site binding in the medicinal applications of these dyes. OX could be beneficial as 
a molecular probe due to its redshifted nature over current commercially available DNA probes 
(30 nm higher than TO). In addition, this dye should have higher fluorescence intensity than 
the commercially available probes due to the exclusion of quinoline from the structure. 
Quinolines are known to experience non-radiative return of decay. These compounds will 
continue to become more useful as the fluorescence approaches the optical window (650-900 
nm) and gets further from the absorption of human tissues.  
5.2.4 Conclusion 
A series of monomethine cyanines were synthesized in good yield with red-shifted 
absorbance properties in comparison to previously synthesized monomethine cyanine dyes. 
Although the benz[c,d]indolium containing monomethine cyanine dyes in this report are non-
fluorescent in free flowing solvent, their fluorescence is “turned on” through the restriction of 
the methine bridge caused by binding to DNA. Computational methods were shown to be 
useful as a predictive tool for determining their optical properties. In keeping everything the 
same except for a single heterocycle, binding affinity to ct-DNA of these heterocycles were 
able to be compared. OX stood out as the best candidate as a starting point for building a new 
molecular probe due to its strong binding affinity and 700-fold increase in fluorescence from 
binding. In addition, IN with a 3,3-dimethylindolenine heterocycle showed almost no binding 
due to the steric hindrance of the dimethyl group. This could be exploited to prevent offsite 
binding. Utilizing the described techniques these dyes could be further developed as potential 
biological probes. Future studies will investigate how different substitutions on the 
heterocycles could increase binding affinities and increase optical activity to various biological 
targets. 
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6 Conclusions 
In conclusion, a series cyanine dyes were systematically designed and synthesized to be 
used as probes in biomedical applications. They were characterized by 1H and 13C NMR and 
HRMS. Near-infrared dyes underwent biodistribution testing in CD-1 mice and fluorophores 
with specific targets were further tested in large animal models. Through screening and rational 
design, specific targeting of the adrenal gland, parathyroid glands, and cartilage was achieved. 
One of these NIR fluorophores synthesized to monitor injected cells in vivo and ex vivo was 
able to penetrate the cell membrane where it was fixed inside the lysosome preventing efflux 
from the cell and could be useful in labeling cells for determining the mechanism of various 
diseases in the body. A few visible range dyes were tested as probes for DNA binding 
comparing. Small changes in the structures were made to determine what may cause or prevent 
binding. One of these dyes showed a large increase in fluorescence upon binding and could 
potentially be used as a DNA probe due to its redshifted properties compared to current probes. 
It is our hope that these findings will lay the foundation for improved diagnosis and treatment 
of diseases. 
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7 Experimental 
7.1 Chemicals and Instruments  
All chemicals and solvents were of American Chemical Society grade or HPLC purity 
and were used as received. All chemicals were purchased from Fisher Scientific (Pittsburgh, 
PA, USA), Sigma-Aldrich (Saint Louis, MO), and Acros Organics. The reactions were 
followed using silica gel 60 F254 thin layer chromatography plates or reversed-phase silica-
gel thin-layer chromatography plates (Merck EMD Millipore, Darmstadt, Germany) with 5% 
methanol in water as the mobile phase. Open column chromatography was utilized for the 
purification of all hydrophobic final compounds using 60-200u, 60A classic column silica gel 
(Dynamic Adsorbents, Norcross, GA) and C18 reversed-phase silica gel (Dynamic Adsorbents, 
Norcross, GA) for highly charged products. The 1H NMR, 13C NMR, and 19F NMR spectra 
were obtained using high quality Kontes NMR tubes (Kimble Chase, Vineland, NJ) rated to 
500 MHz and were recorded on a Bruker Avance (400 MHz) spectrometer. NMR abbreviations 
used throughout the experimental section are as follows: s = singlet, d = doublet, t = triplet, q 
= quartet, p = pentet, m = multiplet, dd = doublet doublets, and bs = broad singlet. High 
resolution mass spectra (HRMS) were obtained at the GSU Mass Spectrometry Facility using 
a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer. The purity of each compound tested 
as determined by using LC/MS instrument possessing a Waters 2487 single wavelength 
absorption detector. The column used in LC was a Waters Delta-Pak 5 μM 100Å 3.9×150 mm 
reversed phase C18 column, with a flow rate of 1 mL/min employing a 5-100% 
Acetonitrile/water/0.1% formic acid gradient; a SEDEX 75 Evaporative light scattering 
detection (ELSD) was also utilized in tandem with liquid chromatography to confirm purity. 
LysoTracker™ was obtained from Molecular Probes (Eugene, OR), and IR786 was purchased 
from Sigma-Aldrich. Imaging experiments were performed by Harvard Medical School at Beth 
Israel Deaconess Medical Center. 
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7.2 Synthesis and Characterization 
7.2.1 Heterocycles 
5-methoxy-2,3,3-trimethyl-3H-indole, 2b: A mixture of 4-methoxyphenylhydrazine 
hydrochloride and 3-methyl-2-butanone was refluxed in glacial acetic acid for 24 hrs. Acetic 
acid was then removed by rotary evaporation and the solution was diluted with 
dichloromethane. Sodium bicarbonate was added to neutralize any remaining acid and the 5-
methoxy-2,3,3-trimethyl-3H-indole 2b was extracted three times with 50 mL dichloromethane, 
dried with magnesium sulfate, and concentrated under vacuum to form a brown oil; 91% yield 
(lit 95% yield148). 
 
5-bromo-2,3,3-trimethyl-3H-indole, 2c: was synthesized by a similar procedure to 72b; 91% 
yield (lit 98% yield148). 
 
5-chloro-2,3,3-trimethyl-3H-indole, 2d: A mixture of 4-chlorophenylhydrazine hydrochloride, 
3-methyl-2-butanone, deionized water, and sulfuric acid were added to a 10 mL microwave 
vessel. The reaction vessel was capped and heated under microwave irradiation for 10 min at 
100 °C. The water was decanted and the reaction was neutralized with a saturated solution of 
sodium bicarbonate. The liquid was poured off and the resulting oil was dissolved in a 
dichloromethane, dried with magnesium sulfate, gravity filtered and concentrated; 100% yield. 
 
2,3,3-trimethyl-3H-indole-5-sulfonate, 2f: was synthesized by our group as previously 
reported.127 
7.2.2 Quaternary Ammonium Salts 
1-ethyl-2,3,3-trimethyl-3H-indol-1-ium iodide, 3b: A mixture of 2,3,3-trimethyl-3H-indole 
and iodobutane were refluxed in acetonitrile for 72 hrs. The reaction was cooled to room 
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temperature. The solution was then poured into ether and the precipitate was filtered; 82% 
yield; mp 217-221 °C (lit mp 165-166 °C63). 
 
1-butyl-2,3,3-trimethyl-3H-indol-1-ium iodide, 3c: was synthesized by a similar procedure to 
3b: 80% yield; mp 116-119 °C (lit mp 102 °C, 83% yield63). 
 
2,3,3-trimethyl-1-(3-phenylpropyl)-3H-indol-1-ium bromide, 3d: was synthesized by a similar 
procedure to 3b: 80% yield; mp 156-158 °C; 1H NMR (400 MHz, DMSO- d6): δ 7.98 (t, J = 
5.2 Hz, 1 H), 7.84 (t, J = 5.2 Hz, 1 H), 7.46 (m, 2 H), 7.29 (m, 5 H), 4.51 (t, J = 8.0 Hz, 2 H), 
2.81 (m, 5 H), 2.17 (m, 2 H), 1.53 (s, 6 H). 13C NMR (100 MHz, DMSO-d6): δ 14.3, 22.0, 28.8, 
31.7, 47.4, 54.1, 115.4, 123.5, 126.0, 128.2, 128.3, 128.8, 129.3, 140.6, 141.0, 141.8, 196.6. 
HRMS m/z: calc. for C20H24N
+ 278.1904, obsd 278.1915. 
 
3-butyl-1,1,2-trimethyl-1H-benzo[e]indol-3-ium iodide, 3f: was synthesized by a similar 
procedure to 3b; mp 142-145oC, 87% yield (lit mp 127-129oC, 90% yield). 
 
2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium bromide, 3h: was 
synthesized by our group as previously reported.149 
 
5-Methoxy-2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indolium bromide, 3i: Yield 
88%; 1H NMR (400 MHz, DMSO-d6): δ 1.55 (s, 6 H), 2.33 (m, 2 H), 2.87 (s, 3 H), 3.12 (s, 9 
H), 3.63 (t, J = 8.4 Hz, 2 H), 3.87 (s, 3 H), 4.48 (t, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.8 Hz, 1 H), 
7.58 (s, 1 H), 8.03 (d, J = 8.8 Hz, 1 H); HRMS m/z: calc for C17H28N2O2
2+ 138.1096, obsd 
138.1010. 
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1,1,2-Trimethyl-3-(3-(trimethylammonio)propyl)-1H-benzo[e]indolium bromide, 3j: Yield 
52%; 1H NMR (400 MHz, DMSO-d6): δ 1.79 (s, 6 H), 2.42-2.37 (m, 2 H), 3.03 (s, 3 H), 3.41 
(s, 9 H), 3.65 (t, J = 8.0 Hz, 2 H), 4.64 (t, J = 8.0 Hz, 2 H), 7.82-7.75 (m, 2 H), 8.26 (t, J = 8.8 
Hz, 2 H), 8.33 (d, J = 8.8 Hz, 1 H), 8.39 (d, J = 8.8 Hz, 1 H). 13C NMR (100 MHz, DMSO-d6): 
δ 15.08, 21.98, 22.11, 45.34, 53.11, 56.13, 62.42, 113.93, 123.89, 127.70, 127.77, 128.93, 
130.20 131.18, 133.55, 137.33, 138.90, 198.11. HRMS m/z: calc for C20H28N2
2+ 148.1121, 
obsd 148.1148. 
 
2,3,3-trimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-5-sulfonate bromide, 3k: 
was synthesized by our group as previously reported.149 
 
5-methoxy-1,2,3,3-tetramethyl-3H-indolium iodide, 3l: Yield 79%; 1H NMR (400 MHz, 
DMSO-d6): δ 1.51 (s, 6 H), 2.71 (s, 3 H), 3.87 (s, 3 H), 3.94 (s, 3 H), 7.15 (dd, J = 8.8 Hz, 1 
H), 747 (s, 1 H), 7.81 (d, J = 8.8 Hz, 1 H). 
 
1-ethyl-5-methoxy-2,3,3-tetramethyl-3H-indolium iodide, 3m: 1H NMR (400 MHz, DMSO-
d6): δ 1.43 (t, J = 8.8 Hz, 3 H), 1.52 (s, 6 H), 2.77 (s, 3 H), 3.87 (s, 3 H), 4.45 (q, J = 8.8 Hz, 2 
H), 7.15 (dd, J = 8.8 Hz, 1 H), 7.49 (s, 1 H), 7.87 (d, J = 8.8 Hz, 1 H). 
 
1-butyl-5-methoxy-2,3,3-trimethyl-3H-indol-1-ium iodide, 3n: was synthesized by a similar 
procedure to 3b; 56% yield; mp 145-147 °C; 1H NMR (400 MHz, DMSO- d6): δ 0.93 (t, J = 
7.2 Hz, 3 H), 1.43 (m, 2 H), 1.53 (s, 6 H), 1.80 (m, 2 H), 2.80 (s, 3 H), 3.86 (s, 3 H), 4.43 (t, J 
= 7.6 Hz, 2 H), 7.13 (dd, J = 10.8 Hz, 1 H), 7.50 (s, 1 H), 7.89 (d, J = 9.2 Hz, 1 H); 13C NMR 
(100 MHz, MeOD-d6): δ 12.4, 19.1, 21.6, 29.0, 47.9, 53.8, 55.7, 108.4, 114.5, 116.0, 133.4, 
143.5, 160.7, 192.3; HRMS m/z: calc for C16H24NO
+ 246.1852, obsd 246.1857. 
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1-ethyl-5-fluoro-2,3,3-trimethyl-3H-indol-1-ium iodide, 3r: was synthesized by a similar 
procedure to 3b: 84% yield; 1H NMR (400 MHz, DMSO- d6): δ 1.43 (t, J = 7.2 Hz, 3 H), 1.54 
(s, 6 H), 2.81 (s, 3 H), 4.48 (t, J = 7.6 Hz, 2 H), 7.51 (t, J = 8.8 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 1 
H), 8.04 (d, J = 8.8 Hz, 1 H). 
 
1-butyl-2-methylbenzo[c,d]indol-1-ium iodide, 9b: was synthesized by our group as 
previously reported.63 
7.2.3 Polymethine Linkers 
N-((1Z,3E)-2-chloro-3-(phenylimino)prop-1-en-1-yl)aniline hydrochloride, 11a: 1H NMR 
(400 MHz, DMSO-d6): δ ppm 7.33 (t, J = 7.2 Hz, 2 H), 7.51 (t, J = 7.6 Hz, 4 H), 7.65 (d, J = 
8.0 Hz, 4 H), 9.43 (s, 1 H), 11.83 (s, 1 H). 
 
N-((E)-(2-methyl-3-((E)-(phenylimino)methyl)cyclohex-2-en-1-ylidene)methyl)aniline 
hydrochloride, 19a: Yield 75%; mp >260 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 1.80  (m, 
2 H), 2.55 (m, 4 H), 2.57 (s, 3 H), 7.23 (t, J = 7.6 Hz, 2 H), 7.44 (t, J = 7.6 Hz, 4 H), 7.65 (t, J 
= 7.6 Hz, 4 H), 8.44 (s, 2 H). 
 
N-((E)-(6-((E)-(phenylimino)methyl)-4,5-dihydro-[1,1'-biphenyl]-2(3H)-
ylidene)methyl)aniline hydrochloride, 19b: Yield 75%; mp 201-203 °C; 1H NMR (400 MHz, 
DMSO-d6): δ ppm 1.95  (m, 2 H), 2.72 (t, J = 6.0 Hz, 4 H), 7.08 (d, J = 7.6 Hz, 4 H), 7.16 (t, 
J = 7.6 Hz, 2 H), 7.26 (s, 2 H), 7.35 (t, J = 7.6 Hz, 4 H), 7.41 (dd, J = 7.6 Hz, 2 H), 7.57 (m, 3 
H). 
7.2.4 Monomethine Cyanine 
1-butyl-2-((1-butylbenzo[c,d]indol-2(1H)-ylidene)methyl)benzo[c,d]indol-1-ium iodide, 20: 
Yield 72%; mp >260 °C; 1H NMR (400 MHz, CDCl3): δ ppm 0.98 (t, J = 7.2 Hz, 6 H), 1.58 
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(m, 4 H), 2.00 (m, 4 H), 4.73 (m, 4 H), 7.00 (s, 1 H), 7.28 (s, 2 H), 7.44 (d, J = 7.2 Hz, 2 H), 
7.51 (t, J = 7.6 Hz, 2 H), 7.62 (t, J = 7.6 Hz, 2 H), 7.73 (d, J = 8.4 Hz, 2 H), 8.09 (d, J = 8.0 
Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ ppm 14.0, 20.3, 31.3, 46.7, 90.4, 112.0, 124.5, 125.6, 
128.2, 128.9, 129.4, 129.6, 130.2, 133.2, 141.5, 159.0. 
7.2.5 Trimethine Cyanines 
1-Butyl-2-[3-(1-butyllbenz[c,d]indol-2(1H)-ylidene)-1-propen-1-yl]- iodide, 21: was 
synthesized as previously published.63  Yield 80% (lit yield 60%). 
 
1,3,3-trimethyl-2-((1E,3E)-3-(1-methylbenzo[c,d]indol-2(1H)-ylidene)prop-1-en-1-yl)-3H-
indol-1-ium bromide, 23a: 55% yield; mp 232-234 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 
1.76 (s, 6 H), 3.81 (s, 6 H), 6.86 (t, J = 7.6 Hz, 2 H), 7.39 (t, J = 7.6 Hz, 1 H), 7.54 (m, 3 H), 
7.67 (t, J = 7.6 Hz, 1 H), 7.72 (d, J = 7.6 Hz, 1 H), 7.98 (t, J = 7.6 Hz, 1 H), 8.27 (d, J = 8.0 
Hz, 1 H), 8.35 (d, J = 7.6 Hz, 1 H), 8.69 (t, J = 13.2 Hz, 1 H); 13C NMR (100 MHz, DMSO-
d6): δ ppm 32.8, 37.4, 54.8, 112.3, 114.5, 117.6, 127.4, 127.7, 129.7, 131.3, 133.9, 134.8, 135.2, 
136.2, 146.6, 147.7, 153.5, 180.7. 
 
2-((1E,3E)-3-(1-Butylbenzo[cd]indol-2(1H)-ylidene)prop-1-en-1-yl)-1,3,3-trimethyl-3H-
indol-1-ium iodide, 23b: 79% yield; mp 128-130 °C; 1H NMR (400 MHz, MeOD-d4): δ ppm 
1.04 (t, J = 7.6 Hz, 3 H), 1.50-1.60 (m, 2 H), 1.85 (s, 6 H), 1.87-1.95 (m, 2 H), 3.84 (s, 3 H), 
4.32 (t, J = 7.6 Hz, 2 H), 6.82 (d, J = 13.6 Hz, 1 H), 6.87 (d, J = 13.6 Hz, 1 H), 7.41 (t, J = 7.2 
Hz, 1 H), 7.39-7.54 (m, 3 H), 7.64 (d, J = 7.6 Hz, 1 H), 7.68 (d, J = 7.6 Hz, 2 H), 7.77 (d, J = 
8.4 Hz, 1 H), 7.95 (t, J = 7.6 Hz, 1 H), 8.23 (d, J = 8.4 Hz, 1 H), 8.38 (d, J = 7.2 Hz, 1 H), 8.91 
(t, J = 13.6 Hz, 1 H); 13C NMR (100 MHz, MeOD-d4): δ ppm 12.8, 14.0, 19.8, 27.3, 29.2, 31.0, 
43.5, 65.4, 105.9, 106.8, 109.2, 111.5, 122,1, 122.5, 125.0, 126.0, 126.6, 128.6, 129.3, 129.5, 
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130.2, 131.1, 141.3, 141.4, 142.5, 149.2, 155.4, 175.9. HRMS m/z: calc. for C29H31N2
+ 
407.2482, obsd 407.2499. 
 
1,3,3-Trimethyl-2-((1E,3E)-3-(1-(3-(trimethylammonio)propyl)benzo[cd]indol-2(1H)-
ylidene)prop-1-en-1-yl)-3H-indol-1-ium bromide, 23c: Yield 75%; mp 134 °C; 1H NMR (400 
MHz, MeOD-d4): δ ppm 1.77 (s, 6 H), 2.23-2.30 (m, 2 H), 3.10 (s, 9 H), 3.62-3.66 (m, 2 H), 
4.33 (t, J = 6.4 Hz, 2 H), 7.05 (d, J = 13.6 Hz, 1 H), 7.12 (d, J = 12.8 Hz, 1 H), 7.42 (t, J = 7.6 
Hz, 1 H), 7.54 (t, J = 7.6 Hz, 1 H), 7.58 (d, J = 7.2 Hz, 1 H), 7.64 (d, J = 8.0 Hz, 1 H), 7.72 (t, 
J = 6.8 Hz, 1 H), 7.74-7.79 (m, 2 H), 8.00 (t, J = 7.6 Hz, 1 H), 8.28 (d, J = 8.4 Hz, 1 H), 8.36 
(d, J = 7.2 Hz, 1 H), 8.73 (t, J = 13.6 Hz, 1 H); 13C NMR (100 MHz, MeOD-d4): δ ppm 22.5, 
28.0, 32.9, 40.9, 50.3, 52.9, 63.0, 107.7, 108.4, 109.3, 113,1, 122.4, 123.0, 125.2, 126.9, 127.1, 
129.2, 129.8, 130.0, 130.2, 130.6, 131.4, 141.4, 142.0, 142.9, 148.8, 154.2, 176.4; HRMS m/z: 
calc. for C31H37N3
2+ 225.6488, obsd 225.6170. 
7.2.6 Pentamethine Cyanines 
2-((1E,3Z)-3-chloro-5-((E)-5-methoxy-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-
5-methoxy-1,3,3-trimethyl-3H-indol-1-ium iodide, 24a: Yield 48%; mp 244-245 °C; 1H NMR 
(400 MHz, MeOD-d4): δ ppm 1.73 (s, 12 H), 3.67 (s, 6 H), 3.85 (s, 6 H), 6.34 (d, J = 12.0 Hz, 
2 H), 6.99 (d, J = 8.0 Hz, 2 H), 7.14 (s, 2 H), 7.29 (d, J = 8.0 Hz, 2 H), 8.23 (d, J = 12 Hz, 2 
H); 13C NMR (100 MHz, DMSO-d6): δ ppm 27.0, 31.9, 49.8, 56.3, 99.7, 109.3, 112.7, 114.0, 
121.8, 136.5, 143.4, 146.1, 158.5, 173.7. HRMS m/z: calc. for C29H34ClN2O2
+ 477.2303, obsd 
477.2327. 
 
2-((1E,3Z)-3-chloro-5-((E)-1-ethyl-5-methoxy-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-
1-yl)-1-ethyl-5-methoxy-3,3-dimethyl-3H-indol-1-ium iodide, 24b: Yield 72%; decomp 223 
°C; 1H NMR (400 MHz, MeOD-d4): δ ppm 1.30 (t, J = 7.2 Hz, 6 H), 1.71 (s, 12 H), 3.82 (s, 6 
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H), 4.18 (q, J = 7.2 Hz, 4 H), 6.21 (d, J = 13 Hz, 2 H), 6.98 (d, J = 12 Hz, 2 H), 7.38 (s, 2 H), 
7.43 (d, J = 12 Hz, 2 H), 8.40 (d, J = 13 Hz, 2 H); 13C NMR (100 MHz, DMSO-d6): δ ppm 
12.4, 24.4, 27.1, 50.0, 56.3, 99.2, 109.5, 112.6, 114.2, 121.7, 135.2, 143.7, 146.4, 158.5, 172.9. 
HRMS m/z: calc. for C29H34ClN2O2
+ 505.2616, obsd 505.2632. 
 
2-((1E,3Z,5E)-3-chloro-5-(3-ethyl-1,1-dimethyl-1H-benzo[e]indol-2(3H)-ylidene)penta-1,3-
dien-1-yl)-3-ethyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide, 24c: Yield 68%, mp 231-233 
°C; 1H NMR (400 MHz DMSO-d6) δ : 1.39 (s, 6 H), 2.00 (s, 12 H), 4.37 (s, 4 H), 6.38 (d, J = 
16 Hz, 2 H), 7.55 (t, 2 H), 7.73 (t, 2 H), 7.84 (d, J = 8.0 Hz, 2H), 8.12 (m, 4 H), 8.27 (d, J = 
4.0 Hz, 2 H) 8.65 (d, J = 16.0 Hz, 2 H); 13C NMR (100 MHz DMSO-d6) δ : 11.8, 25.8, 50.7, 
98.5, 111.1, 121.6, 121.7, 124.6, 126.9, 127.3, 129.4, 130.0, 131.1, 133.4, 138.5, 146.1, 174.1; 
HRMS m/z: calc. for C37H38N2Cl
+ m/z 545.2724, obsd 545.2717. 
 
2-((1E,3Z,5Z)-3-chloro-5-(3-methylnaphtho[2,1-d]thiazol-2(3H)-ylidene)penta-1,3-dien-1-
yl)-3-methylnaphtho[2,1-d]thiazol-3-ium iodide, 24d: Yield 82%, mp 243-245 °C; 1H NMR 
(400 MHz DMSO-d6) δ : 3.92 (s, 6 H), 6.24 (d, J = 12.8 Hz, 2 H), 7.36 (t, J = 7.2 Hz, 2 H), 
7.57 (t, J = 7.2 Hz, 2 H), 7.76 (d, J = 7.6 Hz, 2H), 7.91 (m, 6 H), 8.07 (d, J = 9.2 Hz, 2 H); 13C 
NMR (100 MHz DMSO-d6) δ : 34.7, 97.9, 113.4, 119.4, 121.7, 123.2, 126.3, 128.9, 129.4, 
129.8, 130.5, 140.3, 144.2, 164.3. 
 
1-ethyl-2-((1E,3Z)-5-((E)-1-ethyl-3,3-dimethylindolin-2-ylidene)-3-formylpenta-1,3-dien-1-
yl)-3,3-dimethyl-3H-indol-1-ium iodide, 25: Yield 65%; 1H NMR (400 MHz MeOD-d4) δ : 
1.52 (t, J = 7.2 Hz, 6 H), 1.83 (s, 12 H), 4.40 (q, J = 7.2 Hz, 4 H), 7.36 (m, 2 H), 7.42 (m, 2 H), 
7.53 (d, J = 7.2 Hz, 4 H), 8.32 (d, J = 11.2 Hz, 2 H), 9.90 (s, 1 H). 
7.2.7 Heptamethine Cyanines with an Open Chain 
1,3,3-trimethyl-2-((1E,3E,5E)-7-((E)-1,3,3-trimethylindolin-2-ylidene)hepta-1,3,5-trien-1-
yl)-3H-indol-1-ium iodide, 26a: Yield 53%; mp 159-161 °C; 1H NMR (400 MHz, DMSO-d6): 
δ ppm 1.63 (s, 12 H), 3.58 (s, 6 H), 6.33 (d, J = 13.6 Hz, 2 H), 6.53 (t, J = 12.4 Hz, 2 H), 7.22 
(t, J = 7.2 Hz, 2 H), 7.39 (m, 4 H), 7.57 (d, J = 7.2 Hz, 1 H), 7.78 (t, J = 12.4 Hz, 1 H), 7.84 (t, 
J = 12.4 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6): δ ppm 27.5, 31.6, 49.0, 104.3, 111.3, 
84 
 
122.7, 125.0, 128.8, 141.3, 143.3, 151.1, 172.1. HRMS m/z: calc. for C29H33N2
+ 409.2638, 
obsd 409.2655. 
 
1-ethyl-2-((1E,3E,5E)-7-((E)-1-ethyl-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-trien-1-yl)-
3,3-dimethyl-3H-indol-1-ium iodide, 26b: Yield 90%; mp 142-144 °C; 1H NMR (400 MHz, 
DMSO-d6)  1.27 (t, J = 7.2 Hz, 6 H), 1.63 (s, 12 H), 4.12, (q, J = 7.2 Hz, 4 H), 6.37 (d, J = 
13.6 Hz, 2 H), 6.54 (t, J = 12.8 Hz, 2 H), 7.23 (t, J = 7.2 Hz, 2 H), 7.39 (m, 4 H), 7.58 (d, J = 
7.2 Hz, 2 H), 7.77 (t, J = 12.8 Hz, 1 H), 7.88 (t, J = 12.8 Hz, 2 H). 13C NMR (100 MHz, DMSO-
d6)  12.6, 27.5, 49.1, 103.8, 111.2, 122.9, 125.0, 125.7, 128.9, 141.5, 142.1, 151.5, 171.2. 
 
1-butyl-2-((1E,3E,5E)-7-((E)-1-butyl-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-trien-1-yl)-
3,3-dimethyl-3H-indol-1-ium iodide, 26c: Yield 69%; mp 174-176 °C; 1H NMR (400 MHz, 
MeOD-d4): δ ppm 1.03 (t, J = 7.2 Hz, 6 H), 1.50 (m, 4 H), 1.71 (s, 12 H), 1.79 (m, 4 H), 4.04 
(t, J = 7.2 Hz, 4 H), 6.29 (d, J = 13.6 Hz, 2 H), 6.58 (t, J = 12.4 Hz, 2 H), 7.27 (m, 4 H), 7.41 
(t, J = 7.6 Hz, 2 H), 7.49 (d, J = 7.6 Hz, 4 H), 7.63 (t, J = 12.4 Hz, 1 H), 7.95 (t, J = 12.8 Hz, 2 
H). 13C NMR (100 MHz, MeOD-d4): δ ppm 12.7, 19.7, 26.6, 29.2, 43.3, 103.3, 110.4, 121.9, 
124.6, 128.3, 141.0, 142.3, 151.6. HRMS m/z: calc. for C35H45N2
+ 493.3577, obsd 493.3567. 
 
2-((1E,3E,5E)-7-((E)-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-ylidene)hepta-1,3,5-trien-1-
yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium bromide, 26d: Yield 36%; mp 148-150 
°C; 1H NMR (400 MHz, CDCl3): δ ppm 1.61 (s, 12 H), 2.00 (m, 4 H), 2.74 (t, J = 7.6 Hz, 4 
H), 4.10 (t, J = 7.6 Hz, 4 H), 6.24 (d, J = 13.6 Hz, 2 H), 6.45 (t, J = 12.8 Hz, 2 H), 7.23 (m, 8 
H), 7.31 (m, 6 H), 7.37 (t, J = 7.2 Hz, 2 H), 7.75 (t, J = 12.8 Hz, 1 H), 7.85 (t, J = 12.8 Hz, 2 
H) . 13C NMR (100 MHz, DMSO-d6): δ ppm 27.6, 29.1, 32.5, 43.5, 49.1, 111.3, 122.8, 125.0, 
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126.5, 128.8, 128.8, 141.4, 141.5, 142.5, 171.6. HRMS m/z: calc. for C45H49N2O2
+ 617.3890, 
obsd 617.3896. 
 
3-ethyl-2-((1E,3E,5E,7E)-7-(3-ethyl-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide, 26e: Yield 64%; 
mp 191-193 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 1.33 (t, J = 7.2 Hz, 6 H), 1.91 (s, 12 
H), 4.26 (s, 6 H), 6.45 (d, J = 13.2 Hz, 2 H), 6.59 (t, J = 11.6 Hz, 2 H), 7.50 (t, J = 7.2 Hz, 2 
H), 7.65 (t, J = 7.6 Hz, 2 H), 7.73 (d, J = 8.8 Hz, 2 H), 7.82 (t, J = 13.2 Hz, 1 H), 8.02 (m, 4 
H), 8.25 (d, J = 8.4 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6): δ ppm 13.0, 27.1, 50,9, 103.6, 
111.8, 122.6, 125.1, 128.1, 130.3, 130.8, 131.7, 133.6, 139.8, 150.5, 172.4. HRMS m/z: calc. 
for C39H41N2
+ 537.3264, obsd 537.3255. 
 
3-butyl-2-((1E,3E,5E,7E)-7-(3-butyl-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide, 26f: Yield 61%; 
mp 179-181 °C; 1H NMR (400 MHz, DMSO-d6)  .095 (t, J = 7.2 Hz, 6 H), 1.45 (m, 4 h), 1.73 
(m, 4 H), 1.91 (s, 12 H), 4.21 (t, J = 7.2 Hz, 4 H), 6.44 (d, J = 13.6 Hz, 2 H), 6.60 (t, J = 12.8 
Hz, 2 H), 7.50 (t, J = 7.6 Hz, 2 H), 7.65 (t, J = 7.6 Hz, 2 H), 7.72 (d, J = 8.8 Hz, 2 H), 7.81 (t, 
J = 12.8 Hz, 1 H), 8.04 (m, 6 H), 8.25 (d, J = 8.4 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  
14.3, 19.9, 27.2, 29.9, 43.9, 50.8, 103.8, 112.0, 122.6, 125.1, 125.9, 128.0, 128.1, 130.3, 130.7 
131.6, 133.6, 140.3, 150.5, 172.8.  
 
2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(3-phenylpropyl)-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-3-(3-phenylpropyl)-1H-benzo[e]indol-3-ium 
bromide, 26g: Yield 85%; mp 160-162 °C; 1H NMR (400 MHz, DMSO-d6)  1.88 (s, 12 H), 
2.04 (m, 4 H), 2.75 (t, J = 7.6Hz, 4 H), 4.21 (t, J = 7.2 Hz, 4 H), 6.23 (d, J = 13.6 Hz, 2 H), 
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6.47 (t, J = 12.8 Hz, 2 H), 7.27 (m, 10 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.63 (m, 5 H), 7.32 (m, 
5H), 7.95 (t, J = 13.2 Hz, 2 H), 8.03 (d, J = 9.2 Hz, 4 H), 8.22 (d, J = 8.8 Hz, 2 H) . 13C NMR 
(100 MHz, DMSO-d6)  27.1, 29.4, 32.4, 43.6, 50.8, 103.7, 111.8, 122.6, 125.2, 126.5, 128.0, 
128.1, 128.8, 128.9, 130.3, 130.7, 131.6, 133.6, 140.1, 141.4, 150.4, 172.8. 
 
(2-((1E,3E,5E)-7-((E)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)indolin-2-ylidene)hepta-
1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium) tribromide, 
26h: Yield 46%; mp 191-193 °C 1H NMR (400 MHz, MeOD-d4): δ ppm 1.69 (s 12 H), 2.32 
(m, 4 H), 3.25 (s, 18 H), 3.85 (t, J = 8.0 Hz, 4 H), 4.32 (t, J = 7.6 Hz, 4 H), 6.62 (d, J = 13.2 
Hz, 2 H), 6.77 (t, J = 12.0 Hz, 2 H), 7.23 (t, J = 7.2 Hz, 2 H), 7.40 (t, J = 7.6 Hz, 2 H), 7.49 (t, 
J = 8.0 Hz, 4 H), 7.61 (t, J = 12.0 Hz, 1 H), 7.91 (t, J = 11.6 Hz, 2 H). 13C NMR (100 MHz, 
MeOD-d4): δ ppm 20.9, 26.7, 40.3, 48.9, 52.4, 52.5, 52.5, 63.1, 110.5, 122.0, 124.7, 126.6, 
128.4, 141.0, 141.9, 152.2, 171.6. HRMS m/z: calc. for C39H57N4
3+ 193.8189, obsd 193.7919. 
 
(5-methoxy-2-((1E,3E,5E)-7-((E)-5-methoxy-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)indolin-2-ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-
(trimethylammonio)propyl)-3H-indol-1-ium) tribromide, 26i: Yield 15%; mp 183-185 °C; 1H 
NMR (400 MHz, MeOD-d4): δ ppm 1.65 (s 12 H), 2.30 (m, 4 H), 3.25 (s, 18 H), 3.78 (s, 6 H), 
3.84 (t, J = 8.4 Hz, 4 H), 4.32 (t, J = 8.4 Hz, 4 H), 6.66 (t, J = 12.0 Hz, 2 H), 6.93 (d, J = 8.4 
Hz, 2 H), 7.08 (s, 2 H), 7.43 (m, 3 H), 7.77 (d, J = 10.8 Hz, 2 H). 13C NMR (100 MHz, MeOD-
d4): δ ppm 20.9, 26.6, 40.5, 49.0, 52.5, 54.9, 63.1, 108.7, 111.2, 113.2, 125.9, 135.4, 142.7, 
150.6, 158.2, 170.6. HRMS m/z: calc. for C41H61N4O2
3+ 213.8260, obsd 213.7877. 
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(2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(3-(trimethylammonio)propyl)-1,3-dihydro-2H-
benzo[e]indol-2-ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-3-(3-
(trimethylammonio)propyl)-1H-benzo[e]indol-3-ium) tribromide, 26j: Yield 62%; mp 219-
221 °C; 1H NMR (400 MHz, DMSO-d6)  1.92 (s, 12 H), 2.20 (m, 4 H), 3.16 (s, 18 H), 3.76 
(t, J  = Hz, 4 H), 4.13 (t, J = Hz, 4 H), 6.74 (m, 4 H), 7.50 (t, J = 7.2 Hz, 2 H), 7.65 (t, J = 7.2 
Hz, 2 H), 7.87 (m, 3 H), 8.07 (m, 6 H), 8.26 (d, J = 8.4, 2 H). 13C NMR (100 MHz, DMSO-d6) 
 21.61, 27.27, 50.89, 53.02, 62.81, 104.43, 112.03, 122.67, 122.67, 125.22, 126.66, 128.06, 
128.17, 130.35, 130.77, 131.74, 133.52, 140.05, 172.74. HRMS m/z: calc. for C41H61N4
3+ 
227.1627, obsd 227.1599. 
 
2-((1E,3E,5E,7E)-7-(3,3-dimethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)indolin-2- 
ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-
ium-5- sulfonate bromide, 26k: Yield 53%; mp >260 °C; 1H NMR (400 MHz, DMSO-d6):   
1.68 (s, 12 H), 2.16 (m, 4 H), 3.10 (s, 18 H), 3.51 (t, J = 7.6 Hz, 4 H), 4.14 (t, J = 7.6 Hz, 4 H), 
6.44 (d, J = 13.6 Hz, 2 H), 6.58 (t, J = 13.2 Hz, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 7.68 (d, J = 8.4 
Hz, 2 H), 7.79 (s, 2 H), 8.91 (m, 3 H). 13C NMR (100 MHz, DMSO-d6):  21.30, 27.63, 41.24, 
49.25, 52.98, 62.95, 110.45, 120.39, 126.59, 140.77, 142.31, 145.93. HRMS m/z: calc. for 
C39H55N4O6S2
+ 739.3558, obsd 739.3571. 
 
5-methoxy-2-((1E,3E,5E)-7-((E)-5-methoxy-1,3,3-trimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 26l: Yield 53%; mp 189-190 °C; 1H NMR 
(400 MHz, DMSO-d6): δ ppm 1.62 (s, 12 H), 3.55 (s, 6 H), 3.80 (s, 6 H), 6.23 (d, J = 13.6 Hz, 
2 H), 6.45 (t, J = 12.8 Hz, 2 H), 6.95 (dd, J = 12.8 Hz, 2 H), 7.26 (m, 4 H), 7.67 (t, J = 12.8 Hz, 
1 H), 7.78 (t, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6): δ ppm 24.5, 27.5, 31.6, 49.2, 
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56.2, 109.5, 111.9, 113.7, 136.9, 143.0, 157.9, 171.2. HRMS m/z: calc. for C31H37N2O2
+ 
469.2850, obsd 469.2848. 
 
1-ethyl-2-((1E,3E,5E)-7-((E)-1-ethyl-5-methoxy-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-5-methoxy-3,3-dimethyl-3H-indol-1-ium iodide, 26m: Yield 35%; mp 142-144 °C; 
1H NMR (400 MHz, DMSO-d6)  1.25 (t, J = 7.2 Hz, 6 H) 1.62 (s, 12 H), 3.80 (s, 6 H), 4.08 
(q, J = 7.2 Hz, 4 H), 6.27 (d, J = 13.6 Hz, 2 H), 6.46 (t, J = 12.8 Hz, 2 H), 6.95 (dd, J = 8.8 Hz, 
2 H), 7.27 (m, 4 H), 7.67 (t, J = 12.8 Hz, 1 H), 7.79 (t, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, 
DMSO-d6)  12.7, 27.5, 39.1, 49.3, 56.2, 103.2, 109.7, 111.8, 113.8, 124.9, 135.6, 143.3, 150.2, 
157.9, 170.3. 
 
1-butyl-2-((1E,3E,5E)-7-((E)-1-butyl-5-methoxy-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-5-methoxy-3,3-dimethyl-3H-indol-1-ium iodide, 26n: Yield 86%; mp 106-108 °C; 
1H NMR (400 MHz, MeOD-d4)  1.02 (t, J = 7.2 Hz, 6 H), 1.48 (m, 4 H), 1.69 (s, 12 H), 1.77 
(m, 4 H), 3.85 (s, 3 H), 4.05 (m, 4 H), 6.20 (d, J = 13.2 Hz, 2 H), 6.60 (t, J = 12.0 Hz, 2 H), 
6.96 (d, J = 8.0 Hz, 2 H), 7.10 (s, 2 H), 7.18 (d, J = 8.4 Hz, 2 H), 7.54 (t, J = 11.2 Hz, 1 H), 
7.86 (t, J = 12.8 Hz, 2 H). 13C NMR (100 MHz, MeOD-d4)  12.8, 19.7, 26.6, 29.2, 43.5, 49.0, 
55.0, 102.8, 108.6, 111.0, 113.2, 124.7, 135.8, 142.7, 150.2, 158.2, 170.8. 
 
5-methoxy-2-((1E,3E,5E)-7-((E)-5-methoxy-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-
ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium bromide, 
26o: Yield 41%; mp 131-133 °C; 1H NMR (400 MHz, DMSO-d6)  1.61 (s, 12 H), 1.98 (m, 4 
H), 2.72 (t, J = 7.2 Hz, 4 H), 3.79 (s, 6 H), 4.06 (t, J = 7.2 Hz, 4 H), 6.13 (d, J = 13.6 Hz, 2 H), 
6.37 (t, J = 12.8 Hz, 2 H), 6.93 (dd, J = 8.8 Hz, 2 H), 7.23 (m, 9 H), 7.32 (m, 5H), 7.64 (t, J = 
8.8 Hz, 1 H), 7.77 (t, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  27.6, 29.1, 32.5, 
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43.6, 49.3, 56.2, 103.5, 109.6, 111.9, 113.8, 124.9, 126.5, 128.7, 128.9, 136.1, 141.4, 143.1, 
157.9, 170.7. 
 
1-butyl-2-((1E,3E,5E)-7-((E)-1-butyl-5-chloro-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-5-chloro-3,3-dimethyl-3H-indol-1-ium iodide, 26p: Yield 80%; mp 169-171 °C; 1H 
NMR (400 MHz, MeOD-d4)  1.02 (t, J = 7.2 Hz, 6 H), 1.48 (m, 4 H), 1.71 (s, 12 H), 1.77 (m, 
4 H), 4.07 (t, J = 7.2 Hz, 4 H), 6.30 (d, J = 13.6 Hz, 2 H), 6.60 (t, J = 12.4 Hz, 2 H), 7.26 (d, J 
= 7.6 Hz, 2 H), 7.41 (dd, J = 8.4 Hz, 2 H), 7.55 (s, 2 H), 7.65 (t, J = 12.4 Hz, 1 H), 7.96 (t, J = 
12.8 Hz, 2 H). 13C NMR (100 MHz, MeOD-d4)  12.7, 19.7, 26.4, 29.1, 43.6, 49.0, 103.7, 
111.6, 122.5, 126.2, 128.3, 130.0, 141.1, 142.9, 151.8, 171.5. 
 
5-chloro-2-((1E,3E,5E)-7-((E)-5-chloro-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-
ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium bromide, 
26q: Yield 78%; 1H NMR (400 MHz, DMSO-d6)  1.63 (s, 12 H), 1.98 (m, 4 H), 2.72 (t, J = 
7.6 Hz, 4 H), 4.09 (t, J = 7.2 Hz, 4 H), 6.23 (d, J = 13.6 Hz, 2 H), 6.47 (t, J = 12.8 Hz, 2 H), 
7.29 (m, 13 H), 7.44 (dd, J = 8.4 Hz, 2 H), 7.74 (t, J = 12.8 Hz, 2 H), 7.86 (t, J = 12.8 Hz, 2 
H). 13C NMR (100 MHz, DMSO-d6)  27.4, 29.0, 32.4, 43.8, 49.3, 104.5, 112.7, 123.3, 126.5, 
128.7, 128.8, 129.3, 141.4, 141.5, 143.5, 151.7, 171.5. 
 
1-ethyl-2-((1E,3E,5E)-7-((E)-1-ethyl-5-fluoro-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-5-fluoro-3,3-dimethyl-3H-indol-1-ium iodide, 26r: Yield 56%; mp 165-167 °C; 1H 
NMR (400 MHz, DMSO-d6)  1.26 (t, J = 7.2 Hz, 6 H), 1.64 (s, 12 H), 4.10 (t, J = 7.2 Hz, 4 
H), 6.35 (d, J = 14.0 Hz, 2 H), 6.53 (t, J = 12.8 Hz, 2 H), 7.24 (m, 2 H), 7.39 (m, 2 H), 7.58 (m, 
2 H), 7.75 (t, J = 12.8 Hz, 1 H), 7.86 (t, J = 12.8 Hz, 2 H). 19F NMR (115 MHz, DMSO-d6)  
-119.8. 
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1-butyl-2-((1E,3E,5E)-7-((E)-1-butyl-5-fluoro-3,3-dimethylindolin-2-ylidene)hepta-1,3,5-
trien-1-yl)-5-fluoro-3,3-dimethyl-3H-indol-1-ium iodide, 26s: Yield 81%; mp 225-227 °C; 1H 
NMR (400 MHz, DMSO-d6)  0.93 (t, J = 7.2 Hz, 6 H), 1.38 (m, 4 H), 1.64 (s, 12 H), 1.67 (m, 
4 H), 4.06 (t, J = 7.2 Hz, 4 H), 6.35 (d, J = 14.0 Hz, 2 H), 6.53 (t, J = 12.4 Hz, 2 H), 7.23 (m, 
2 H), 7.39 (m, 2 H), 7.58 (m, 2 H), 7.75 (t, J = 12.4 Hz, 1 H), 7.86 (t, J = 12.8 Hz, 2 H). 19F 
NMR (115 MHz, DMSO-d6)  -120.0. 
 
5-fluoro-2-((1E,3E,5E)-7-((E)-5-fluoro-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-
ylidene)hepta-1,3,5-trien-1-yl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-ium bromide, 
26t: Yield 71%; mp 135-137 °C; 1H NMR (400 MHz, DMSO-d6)  1.62 (s, 12 H), 1.98 (m, 4 
H), 2.73 (t, J = 7.6 Hz, 4 H), 4.08 (t, J = 7.6 Hz, 4 H), 6.20 (d, J = 13.6 Hz, 2 H), 6.44 (t, J = 
12.4 Hz, 2 H), 7.23 (m, 8 H), 7.34 (m, 6 H), 7.57 (dd, J = 12.4 Hz, 2 H), 7.71 (t, J = 12.4 Hz, 
1 H), 7.83 (t, J = 12.8 Hz, 2 H). 19F NMR (115 MHz, DMSO-d6)  -120.0. 
7.2.8 Heptamethine Cyanines Containing a Cyclic Ring in the Methine Chain 
2-((E)-2-((E)-2-chloro-3-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohex-1-en-
1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 27a: was synthesized as previously 
described.150 1H NMR (400 MHz, DMSO-d6)  1.67 (s, 12 H), 1.85 (m, 2 H), 2.72 (t, J = 6.0 
Hz, 4 H), 3.68 (s, 6 H), 6.30 (t, J = 14.0 Hz, 2 H), 7.28 (m, 2 H), 7.44 (m, 4 H), 7.62 (d, J = 7.2 
Hz, 2 H), 8.25 (d, J = 14.4 Hz, 2 H). 
 
3-(2-((E)-2-((E)-2-chloro-3-((E)-2-(1,1-dimethyl-3-(3-sulfonatopropyl)-1,3-dihydro-2H-
benzo[e]indol-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,1-dimethyl-1H-
benzo[e]indol-3-ium-3-yl)propane-1-sulfonate, 27b: Yield 71%; 1H NMR (400 MHz, DMSO-
d6)  1.25 (t, J = 7.2 Hz, 6 H), 1.64 (s, 12 H), 4.10, (q, J = 7.2 Hz, 4 H), 6.37 (d, J = 13.6 Hz, 2 
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H), 6.56 (t, J = 12.8 Hz, 2 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.45 (dd, J = 6.8 Hz, 2 H), 7.76 (m, 3 
H), 7.89 (t, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  12.6, 27.3, 49.3, 104.2, 112.6, 
123.4, 126.3, 128.8, 129.3, 141.1, 143.6, 151.8, 171.0. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-5-methoxy-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-5-methoxy-1,3,3-trimethyl-3H-indol-1-ium 
iodide, 27e: Yield 71%; mp 238-240 °C; 1H NMR (400 MHz, DMSO-d6)  1.66 (s, 12 H), 1.84 
(m, 2 H), 2.68 (t, J = 7.6 Hz, 4 H), 3.65 (s, 6 H), 3.82 (s, 6 H), 6.21 (d, J = 14.4 Hz, 2 H), 6.99 
(dd, J = 8.8 Hz, 2 H), 7.30 (s, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 8.174 (d, J = 14.0 Hz, 2 H). 13C 
NMR (100 MHz, DMSO-d6)  20.9, 26.3, 27.7, 32.0, 49.4, 56.3, 101.8, 109.5, 112.5, 114.0, 
125.6, 136.8, 141.9, 143.2, 147.0, 158.3, 172.0. 
 
5-bromo-2-((E)-2-((E)-3-(2-((E)-5-bromo-1,3,3-trimethylindolin-2-ylidene)ethylidene)-2-
chlorocyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 27f: Yield 76%; mp 
247-249 °C; 1H NMR (400 MHz, DMSO-d6)  1.68 (s, 12 H), 1.86 (t, J = 6.0 Hz, 2 H), 2.72 
(m, 4 H), 3.67 (s, 6 H), 6.29 (d, J = 14.4 Hz, 2 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.62 (dd, J = 8.4 
Hz, 2 H), 7.89 (s, 2 H), 8.24 (d, J = 14.0 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  20.8, 
26.3, 27.5, 32.1, 49.5, 102.7, 113.7, 117.9, 126.1, 127.2, 131.7, 142.7, 143.2, 143.7, 148.5, 
172.7. 
 
2-((E)-2-((E)-2-chloro-3-((E)-2-(1,1-dimethyl-3-(3-phenylpropyl)-1,3-dihydro-2H-
benzo[e]indol-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,1-dimethyl-3-(3-
phenylpropyl)-1H-benzo[e]indol-3-ium bromide, 27g: Yield 72%; mp 211-213 °C; 1H NMR 
(400 MHz, DMSO-d6)  1.88 (m, 2 H), 1.94 (s, 12 H), 2.09 (m, 4 H), 2.56 (m, 4 H), 2.80 (t, J 
= 7.6 Hz, 4 H), 4.33 (t, J = 7.6 Hz, 4 H), 6.15 (d, J = 13.6 Hz, 2 H), 7.29 (m, 10 H), 7.53 (t, J 
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= 7.6 Hz, 2 H), 7.66 (t, J = 7.6 Hz, 2 H), 7.76 (d, J = 8.4 Hz, 2 H), 8.09 (t, J = 8.8 Hz, 4 H), 
8.31 (t, J = 13.2 Hz, 4 H). 13C NMR (100 MHz, DMSO-d6)  26.3, 27.4, 29.2, 32.4, 43., 51.2, 
101.4, 112.1, 122.7, 125.5, 126.5, 127.9, 128.3, 128.8, 128.9, 130.4, 130.9, 131.9, 134.1, 140.1, 
141.3, 142.3, 147.8, 173.7. 
 
5-chloro-2-((E)-2-((E)-2-chloro-3-(2-((E)-5-chloro-3,3-dimethyl-1-(3-phenylpropyl)indolin-
2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(3-phenylpropyl)-3H-indol-1-
ium bromide, 27h: Yield 84%; mp 206-208 °C; 1H NMR (400 MHz, DMSO-d6)  1.65 (s, 12 
H), 1.82 (m, 2 H), 2.02 (m, 4 h), 2.75 (t, J = 7.2 Hz, 4 H), 4.19 (t, J = 6.8 Hz, 4 H), 6.10 (d, J 
= 14.4 Hz, 2 H), 7.26 (m, 10 H), 7.48 (m, 4 H), 7.80 (s, 2 H), 8.20 (d, J = 14.0 Hz, 2 H) 13C 
NMR (100 MHz, DMSO-d6)  26.2, 27.7, 28.8, 32.4, 49.6, 102.1, 113.3, 123.5, 126.5, 127.2, 
128.7, 128.9, 129.9, 141.2, 141.4, 143.5, 143.5, 148.8, 172.4. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-1-ethyl-5-fluoro-3,3-dimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-ethyl-5-fluoro-3,3-dimethyl-3H-indol-1-ium 
iodide, 27i: Yield 71%; mp >260 °C; 1H NMR (400 MHz, DMSO-d6)  1.29 (t, J = 7.2 Hz, 6 
H), 1.67 (s, 12 H), 1.85 (m, 4 H), 2.71 (t, J = 6.0 Hz, 4 H), 4.25 (q, J = 7.2 Hz, 4 H), 6.29 (d, J 
= 14.0 Hz, 2 H), 7.30 (t, J = 8.8 Hz, 2 H), 7.48 (d, J = 8.8 Hz, 2 H), 7.64 (d, J = 8.4 Hz, 2 H) 
8.24 (d, J = 14.4 Hz, 2 H). 19F NMR (115 MHz, DMSO-d6)  -119.21. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-5-fluoro-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-5-fluoro-3,3-dimethyl-1-(3-phenylpropyl)-3H-
indol-1-ium bromide, 27j: Yield 66%; mp 143-145 °C; 1H NMR (400 MHz, DMSO-d6)  1.65 
(s, 12 H), 1.84 (m, 4 H), 2.03 (m, 4 H), 2.75 (t, J = 7.2 Hz, 4 H), 4.19 (t, J = 7.2 Hz, 4 H), 6.07 
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(d, J = 14.4 Hz, 2 H), 7.28 (m, 12 H), 7.46 (m, 2 H), 7.63 (m, 2 H), 8.19 (d, J = 14.0 Hz, 2 H). 
19F NMR (115 MHz, DMSO-d6)  -119.17. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-5-methoxy-3,3-dimethyl-1-(3-phenylpropyl)indolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-5-methoxy-3,3-dimethyl-1-(3-phenylpropyl)-
3H-indol-1-ium bromide, 27l: Yield 78%; mp 135-137 °C; 1H NMR (400 MHz, DMSO-d6)  
1.64 (s, 12 H), 1.81 (t, J = 7.6 Hz, 2 H), 2.02 (m, 4 H), 2.74 (t, J = 7.6 Hz, 4 H), 3.37 (m, 4 H), 
3.81 (s, 6 H), 4.16 (t, J = 7.6 Hz, 4 H), 6.00 (d, J = 14.4 Hz, 2 H), 6.98 (dd, J = 8.4 Hz, 2 H), 
7.25 (m, 6 H), 7.33 (m, 8 H), 8.14 (d, J = 14.4 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  
20.7, 26.2, 27.8, 28.9, 32.4, 43.8, 49.6, 53.3, 101.3, 109.6, 112.6, 114.1, 125.6, 126.5, 128.8, 
128.9, 135.9, 141.3, 142.1, 143.3, 147.3, 158.3, 171.5. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclopent-1-en-
1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 28a: Yield 53%; mp >260 °C; 1H NMR 
(400 MHz, CDCl3)  1.73 (s, 12 H), 3.10 (m, 4 H), 3.77 (s, 6 H), 6.13 (d, J = 14.0 Hz, 2 H), 
7.16 (d, J = 8.0 Hz, 2 H), 7.24 (t, J = 8.0 Hz, 2 H), 7.40 (m, 4 H), 7.83 (d, J = 14.0 Hz, 2 H); 
13C NMR (100 MHz, CDCl3)  27.1, 28.0, 32.6, 49.0, 102.9, 110.6, 122.0, 125.1, 128.8, 136.8, 
138.3, 140.9 142.9, 151.8, 171.4. HRMS m/z: calc for C31H34N2Cl
+ 469.2405, obsd 469.2387. 
 
2-((E)-2-((E)-2-chloro-3-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohept-1-en-
1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 28b: Yield 79%; mp 139-141 °C; 1H NMR 
(400 MHz, CDCl3)  1.74 (s, 12 H), 1.91 (m, 4 H), 2.83 (m, 4 H), 3.79 (s, 6 H), 6.31 (d, J = 
14.4 Hz, 2 H), 7.19 (d, J = 8.00 Hz, 2 H), 7.26 (t, J = 7.2 Hz, 2 H), 7.38 (d, J = 7.2 Hz, 2 H), 
7.44 (t, J = 7.2 Hz, 2 H), 8.37 (d, J = 14.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3)  23.9, 26.9, 
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28.0, 32.8, 49.2, 101.4, 110.7, 122.0, 125.2, 128.8, 131.2, 142.8, 147.2, 154.7, 173.1. HRMS 
m/z: calc for C33H38N2Cl
+ 497.2718, obsd 497.2698. 
 
2-((E)-2-((E)-2-bromo-3-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohex-1-en-
1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 29a: Yield 74%; mp >260 °C; 1H NMR 
(400 MHz, DMSO-d6)  1.69 (s, 12 H), 1.85 (m, 2 H), 3.91 (m, 4 H), 3.69 (s, 6 H), 6.23 (d, J 
= 14.4 Hz, 2 H), 7.29 (m, 2 H), 7.44 (m, 4 H), 7.63 (d, J = 7.2 Hz, 2 H), 8.26 (d, J = 14.0, 2 H). 
13C NMR (100 MHz, DMSO-d6)  27.5, 31.9, 49.3, 102.6, 111.9, 122.8, 125.6, 128.4, 129.0, 
141.4, 143.3, 144.9, 146.7, 173.1. HRMS m/z: calc for C32H36N2Br
+ 527.2056, obsd 527.2040. 
 
5-bromo-2-((E)-2-((E)-2-bromo-3-(2-((E)-5-bromo-1-butyl-3,3-dimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-butyl-3,3-dimethyl-3H-indol-1-ium iodide, 
29b: Yield 65%; mp 195-197 °C; 1H NMR (400 MHz, CDCl3)  1.02 (t, J = 7.2 Hz, 6 H), 1.51 
(m, 4 H), 1.60 (s, 12 H), 1.82 (m, 4 H), 2.00 (m, 2 H), 2.80 (t, J = 6.0 Hz, 4 H), 4.25 (t, J = 7.2 
Hz, 4 H), 6.31 (d, J = 14.0 Hz, 2 H), 7.08 (d, J = 8.4 Hz, 2 H), 7.48 (s, 2 H), 7.53 (d, J = 8.4 
Hz, 2 H), 8.33 (d, J = 14.0, 2 H). 13C NMR (100 MHz, CDCl3)  13.9, 20.3, 27.9, 28.0, 29.5, 
38.1, 45.2, 49.3, 59.5, 102.5, 112.4, 118.3, 125.6, 128.5, 130.3, 134.4, 141.4, 143.0, 144.1, 
147.1, 153.9, 171.6. 
 
1,3,3-trimethyl-2-((E)-2-((E)-2-methyl-3-(2-((E)-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3H-indol-1-ium iodide, 30a: Yield 71%; mp 
217-219 °C; 1H NMR (400 MHz, CDCl3)  ppm 1.73 (s, 12 H), 1.92 (t, J = 5.6 Hz, 2 H), 2.43 
(s, 3 H), 2.62 (t, J = 5.6 Hz, 4 H), 3.72 (s, 6 H), 6.16 (d, J = 13.6 Hz, 2 H), 7.16 (d, J = 8.0 Hz, 
2 H), 7.23 (d, J = 7.6 Hz, 2 H), 7.38 (m, 4 H), 8.05 (d, J = 13.2 Hz, 2 H). 13C NMR (100 MHz, 
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CDCl3)  ppm 15.1, 20.9, 25.7, 28.3, 32.2, 100.6, 110.3, 122.1, 124.8, 128.7, 132.1, 140.5, 
142.4, 156.0, 171.5. HRMS m/z: calc. for C33H39N2
+ 463.3108, obsd 463.3091. 
 
5-methoxy-2-((E)-2-((E)-3-(2-((E)-5-methoxy-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
2-methylcyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30b: Yield 62%; 
mp 122-124 °C; 1H NMR (400 MHz, CDCl3)  1.72 (s, 12 H), 1.91 (m, 2 H), 2.40 (s, 3 H), 
2.58 (t, J = 6.4Hz, 4 H), 3.67 (s, 6 H), 3.88 (s, 6 H), 6.06 (d, J = 13.6 Hz, 2 H), 6.91 (dd, J = 
8.4 Hz, 2 H), 6.95 (s, 2 H), 7.09 (d, J = 8.4 Hz, 2 H), 7.99 (d, J = 13.6 Hz, 2 H). 13C NMR (100 
MHz, CDCl3)  15.0, 21.0, 25.6, 28.3, 32.3, 48.9, 56.1, 100.1, 109.3, 110.9, 113.1, 131.2, 
136.6, 141.2, 142.2, 157.9, 170.5. 
 
5-bromo-2-((E)-2-((E)-3-(2-((E)-5-bromo-1,3,3-trimethylindolin-2-ylidene)ethylidene)-2-
methylcyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30c: Yield 73%; mp 
233-235 °C; 1H NMR (400 MHz, CDCl3)  1.72 (s, 12 H), 1.91 (t, J = 6.0 Hz, 2 H), 2.42 (s, 3 
H), 2.62 (t, J = 6.0 Hz, 4 H), 3.72 (s, 6 H), 6.17 (d, J = 13.6 Hz, 2 H), 7.05 (d, J = 8.4 Hz, 2 H), 
7.45 (s, 2 H), 7.51 (d, J = 8.8 Hz, 2 H), 8.02 (d, J = 13.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3) 
 15.2, 20.8, 25.7, 28.3, 32.6, 48.8, 101.1, 111.8, 117.7, 125.4, 131.7, 132.9, 142.1, 142.3, 
156.4, 170.8. 
 
5-chloro-2-((E)-2-((E)-3-(2-((E)-5-chloro-1,3,3-trimethylindolin-2-ylidene)ethylidene)-2-
methylcyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30d: Yield 68%; mp 
228-230 °C; 1H NMR (400 MHz, CDCl3)  1.72 (s, 12 H), 1.91 (m, 2 H), 2.42 (s, 3 H), 2.62 (t, 
J = 6.0 Hz, 4 H), 3.72 (s, 6 H), 6.17 (d, J = 13.6 Hz, 2 H), 7.09 (d, J = 8.4 Hz, 2 H), 7.31 (s, 2 
H), 7.36 (dd, J = 8.8 Hz, 2 H), 8.03 (d, J = 14.0 Hz, 2 H). 13C NMR (100 MHz, CDCl3)  15.2, 
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20.8, 25.7, 28.2, 32.6, 48.8, 101.2, 111.3, 122.6, 128.8, 130.3, 132.9, 141.7, 142.0, 142.3, 
156.2, 170.9. 
 
2-((E)-2-((E)-3-((E)-2-(1,1-dimethyl-3-(3-phenylpropyl)-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-2-methylcyclohex-1-en-1-yl)vinyl)-1,1-dimethyl-3-(3-phenylpropyl)-1H-
benzo[e]indol-3-ium bromide, 30e: Yield 65%; mp 148-150 °C; 1H NMR (400 MHz, DMSO-
d6)  1.25 (t, J = 5.6 Hz, 2 H), 1.94 (s, 12 H), 2.09 (m, 4 H), 2.37 (m, 4 H), 2.45 (s, 3 H), 2.80 
(t, J = 7.2 Hz, 4 H), 4.27 (t, J = 7.2 Hz, 4 H), 6.03 (d, J = 14.0 Hz, 2 H), 7.29 (m, 10 H), 7.50 
(t, J = 7.2 Hz, 2 H), 7.65 (t, J = 7.2 Hz, 2 H), 7.70 (d, J = 9.2 Hz, 2 H), 8.07 (m, 6 H), 8.25 (d, 
J = 8.8 Hz, 2 H). 13C NMR (100 MHz, DMSO-d6)  15.0, 25.3, 27.6, 29.0, 32.5, 43.5, 50.8, 
100.0, 111.9, 122.6, 125.1, 126.5, 128.0, 128.1, 128.8, 128.9, 130.3, 130.8, 131.7, 133.4, 140.3, 
141.3, 154.7, 172.4. 
 
1,3,3-trimethyl-2-((E)-2-((E)-6-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-3H-indol-1-ium iodide, 30f: Yield 77%; mp >260 °C; 
1H NMR (400 MHz, CDCl3)  1.11 (s, 12 H), 1.95 (m , 2 H), 2.68 (t, J = 6.0 Hz, 4 H), 3.58 (s, 
6 H), 6.17 (d, J = 14.0 Hz, 4 H), 7.16 (m, 4 H), 7.25 (d, J = 8.4 Hz, 2 H), 7.34 (m, 4 H),  7.46 
(d, J = 7.6 Hz, 2 H), 7.62 (m, 3 H). 13C NMR (100 MHz, CDCl3)  21.3, 24.5, 27.3, 31.5, 48.5, 
100.7, 111.3, 122.7, 124.9, 128.5, 128.8, 129.0, 129.6, 131.0, 139.1, 140.9, 143.3, 147.3, 161.5, 
172.1. HRMS m/z: calc. for C38H41N2
+ 525.3264, obsd 525.3241. 
 
5-methoxy-2-((E)-2-((E)-6-(2-((E)-5-methoxy-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30g: 
Yield 73%; mp 238-240 °C; 1H NMR (400 MHz, CDCl3)  1.17 (s, 12 H), 2.06 (m, 2 H), 2.70 
(t, J = 6.4 Hz, 4 H), 3.61 (s, 6 H), 3.82 (s, 6 H), 6.03 (d, J = 14.0 Hz, 2 H), 6.76 (s, 2 H), 6.86 
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(d, J = 8.8 Hz, 2 H), 7.04 (d, J = 8.4 Hz, 2 H), 7.10 (d, J = 14.0 Hz, 2 H), 7.21 (d, J = 6.8 Hz, 
2 H), 7.55 (m, 3 H); 13C NMR (100 MHz, CDCl3)  21.2, 24.9, 27.5, 32.2, 48.5, 55.9, 99.8, 
109.1, 110.9, 112.8, 128.0, 128.4, 129.5, 131.4, 136.5, 139.1, 142.2, 146.8, 157.8, 161.3, 171.0. 
 
5-bromo-2-((E)-2-((E)-6-(2-((E)-5-bromo-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30h: 
Yield 75%; mp >260 °C; 1H NMR (400 MHz, CDCl3)  1.12 (s, 12 H), 2.08 (m, 2 H), 2.76 (t, 
J = 6.4 Hz, 4 H), 3.66 (s, 6 H), 6.15 (d, J = 14.0 Hz, 2 H), 6.99 (d, J = 8.4 Hz, 2 H), 7.15 (d, J 
= 14.0 Hz, 2 H),  7.21 (dd, J = 7.6 Hz, 2 H), 7.46 (dd, J = 8.4 Hz, 2 H), 7.56 (m, 3 H). 13C NMR 
(100 MHz, CDCl3)  21.0, 25.0, 27.5, 32.5, 48.4, 100.9, 111.7, 117.7, 125.3, 128.2, 128.5, 
129.4, 131.5, 133.2, 138.7, 142.0, 142.4, 148.1, 162.9, 171.2. 
 
5-chloro-2-((E)-2-((E)-6-(2-((E)-5-chloro-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 30i: 
Yield 78%; mp >260 °C; 1H NMR (400 MHz, CDCl3)  1.17 (s, 12 H), 2.07 (m, 2 H), 2.74 (t, 
J = 6.4 Hz, 4 H), 3.65 (s, 6 H), 6.12 (d, J = 14.0 Hz, 2 H), 7.05 (d, J = 8.4 Hz, 2 H), 7.17 (m, 6 
H), 7.30 (t, J = 8.4 Hz, 2 H),  7.56 (m, 3 H); 13C NMR (100 MHz, CDCl3)  21.1, 25.0, 27.5, 
32.5, 48.5, 100.8, 111.3, 122.5, 128.2, 128.5, 128.7, 129.4, 130.2, 133.0, 138.7, 141.5, 142.1, 
148.2, 163.0, 171.4. 
 
1,1,3-trimethyl-2-((E)-2-((E)-6-((E)-2-(1,1,3-trimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-1H-benzo[e]indol-3-ium 
iodide, 30j: Yield 63%; mp >260 °C; 1H NMR (400 MHz, CDCl3)  1.50 (s, 12 H), 2.11 (m, 2 
H), 2.79 (t, J = 6.4 Hz, 4 H), 3.77 (s, 6 H), 6.16 (d, J = 14.0 Hz, 2 H), 7.30 (m, 2 H), 7.44 (m, 
4 H), 7.55 (t, J = 7.6 Hz, 2 H), 7.66 (m, 3 H), 7.92 (m, 6 H); 13C NMR (100 MHz, CDCl3)  
98 
 
21.2, 25.0, 27.1, 32.5, 50.2, 99.9, 110.5, 121.9, 124.7, 127.5, 128.0, 128.3, 128.6, 129.5, 130.1, 
130.5, 131.7, 132.2, 132.9, 139.0, 140.2, 147.1, 162.0, 173.3. 
 
2-((E)-2-((E)-4-chloro-5-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1,2,5,6-
tetrahydro-[1,1'-biphenyl]-3-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 31a: Yield 
72%; mp 171-173 °C; 1H NMR (400 MHz, CDCl3)  1.68 (s, 12 H), 2.70 (m, 2 H), 3.04 (m, 1 
H), 3.15 (m, 2 H), 3.65 (s, 6 H), 6.32 (d, J = 14.0 Hz, 2 H), 7.29 (m, 3 H), 7.41 (m, 6 H), 7.48 
(d, J = 7.2 Hz, 2 H), 7.63 (d, J = 7.6 Hz, 2 H), 8.31 (d, J = 14.0 Hz, 2 H). 13C NMR (100 MHz, 
CDCl3)  27.8, 32.0, 33.6, 38.7, 49.3, 102.4, 111.9, 122.8, 125.6, 126.3, 127.1, 127.9, 129.0, 
141.5, 143.3, 145.4, 147.7, 173.3; HRMS m/z: calc. for C38H40N2Cl
+ 559.2875, obsd 559.2855. 
 
2-((E)-2-((E)-4-chloro-5-((E)-2-(1,1,3-trimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-1,2,5,6-tetrahydro-[1,1'-biphenyl]-3-yl)vinyl)-1,1,3-trimethyl-1H-
benzo[e]indol-3-ium iodide, 31b: Yield 82%; mp 182-184 °C; 1H NMR (400 MHz, CDCl3)  
1.97 (s, 12 H), 2.74 (t, J = 12.8 Hz, 2 H), 3.08 (m, 1 H), 3.20 (m, 2 H), 3.78 (s, 6 H), 6.37 (d, J 
= 14.4 Hz, 2 H), 7.31 (t, J = 7.2 Hz, 1 H), 6.42 (t, J = 7.2 Hz, 2 H), 7.52 (m, 4 H), 7.67 (t, J = 
7.2 Hz, 2 H), 7.77 (d, J = 8.8 Hz, 2 H), 8.09 (t, J = 9.2 Hz, 4 H), 8.31 (d, J = 8.4 Hz, 2 H), 8.43 
(d, J = 14.4 Hz, 2 H). 13C NMR (100 MHz, CDCl3)  27.3, 32.4, 33.7, 51.1, 102.0, 112.2, 122.7, 
125.4, 126.3, 127.1, 127.8, 127.9, 128.2, 129.0, 130.4, 130.8, 131.9, 134.0, 140.9, 142.3, 145.4, 
147.2, 174.5. 
 
2-((E)-2-((E)-2-(4-(2-carboxyethyl)phenoxy)-3-(2-((E)-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 32: 81% 
yield; mp 161-163 °C; 1H NMR (400 MHz, MeOD-d4): δ 1.35 (s, 12 H), 2.05 (m, 2 H), 2.52 
(t, J = 7.2 Hz, 2 H), 2.75 (t, J = 6.0 Hz, 4 H), 2.86 (t, J  = 7.2 Hz, 2 H), 3.60 (s, 6 H), 6.13 (d, J 
= 14.4 Hz, 2 H), 7.03 (d, J = 8.8 Hz, 2 H), 7.25 (m, 6 H), 7.38 (m, 4 H), 8.00 (d, J = 14.4 Hz, 
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2 H); 13C NMR (100 MHz, MeOD-d4): δ ppm 21.0, 23.8, 26.6, 29.3, 29.8, 30.1, 36.0, 48.7, 
99.5, 110.2, 114.3, 121.7, 121.8, 124.6, 128.2, 129.9, 135.3, 141.0, 142.0, 142.8, 158.5, 164.0, 
172.9. HRMS m/z: calcd for C41H45N2O3
+ m/z 613.3425, obsd 613.3430. 
 
2-((E)-2-((E)-2-((4-(2-carboxyethyl)phenyl)amino)-3-(2-((E)-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 33: 
Yield 72%; 1H NMR (400 MHz, CDCl3): δ 1.77 (s, 12 H), 1.98 (m, 2 H), 2.66 (t, J = 5.6 Hz, 4 
H), 2.88 (t, J = 5.6 Hz, 4 H), 3.37 (s, 6 H), 5.63 (d, J  = 13.6 Hz, 2 H), 6.87 (d, J = 8.0 Hz, 2 
H), 7.07 (t, J = 7.6 Hz, 2 H), 7.32 (t, J = 8.0 Hz, 2 H), 7.38 (t, J = 7.6 Hz, 2 H), 7.45 (d, J = 7.2 
Hz, 2 H), 7.52 (t, J = 7.2 Hz, 2 H), 7.89 (d, J = 12.8 Hz, 2 H); 13C NMR (100 MHz, CDCl3): δ 
ppm 22.4, 22.6, 23.8, 28.3, 29.7, 29.9, 94.2, 107.9, 112.3, 121.9, 122.2, 126.7, 128.3, 129.4, 
132.1, 139.3, 140.0, 142.9, 143.8, 165.9. 
 
 
2-((E)-2-((E)-2-((4-(azidosulfonyl)phenyl)amino)-3-(2-((E)-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 39: 
Yield 46%; 1H NMR (400 MHz, CDCl3): δ 0.89 (m, 4 H), 1.27 (s, 12 H), 2.19 (t, J = 6.0 Hz, 2 
H), 3.37 (s, 6 H), 6.59 (m, 2 H), 6.67 (m, 2 H), 6.92 (d, J = 8.8 Hz, 4 H), 7.33 (d, J  = 8.8 Hz, 
4 H), 8.31 (m, 2 H), 8.45 (d, J = 11.6 Hz, 2 H). 
 
2-((E)-2-((E)-2-((2-hydroxyethyl)amino)-3-(2-((E)-1,3,3-trimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 40: 
Yield 76%; mp 160-162 °C; 1H NMR (400 MHz, CDCl3)  1.66 (s, 12 H), 1.86 (m, 2 H), 2.52 
(t, J = 6.8 Hz, 4 H), 3.45 (s, 6 H), 3.60 (s, 3 H), 4.03 (d, J = 7.6 Hz, 2 H), 4.11 (d, J = 7.6 Hz, 
2 H), 5.64 (d, J = 13.2 Hz, 2 H), 6.93 (d, J = 8.0 Hz, 2 H), 7.10 (t, J = 7.6 Hz, 2 H), 7.31 (m, 4 
H), 7.70 (d, J = 13.2 Hz, 2 H); 13C NMR (100 MHz, CDCl3)  21.7, 25.0, 29.2, 45.2, 47.9, 
59.2, 59.9, 94.7, 108.4, 122.1, 123.0, 123.6, 128.1, 140.2, 141.8, 143.5, 143.5. 
 
1,3,3-trimethyl-2-((E)-2-((E)-2-(2-(trimethylammonio)ethoxy)-3-(2-((E)-1,3,3-
trimethylindolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3H-indol-1-ium diiodide, 
41: Yield 70%; mp 108-110 °C; 1H NMR (400 MHz, CDCl3)  1.76 (s, 12 H), 1.97 (m, 2 H), 
2.62 (t, J = 6.0 Hz, 4 H), 3.69 (s, 6 H), 3.72 (s, 9 H), 4.62 (d, J = 5.6 Hz, 2 H), 4.67 (d, J = 5.2 
Hz, 2 H), 5.95 (d, J = 14.0 Hz, 2 H), 7.12 (d, J = 8.0 Hz, 2 H), 7.25 (t, J = 7.6 Hz, 2 H), 7.39 
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(t, J = 7.6 Hz, 2 H), 7.44 (d, J = 7.6 Hz, 2 H), 8.00 (d, J = 14.0 Hz, 2 H); 13C NMR (100 MHz, 
CDCl3)  20.8, 24.9, 28.4, 32.3, 49.4, 55.3, 64.2, 70.1, 99.9, 110.2, 122.6, 123.2, 125.2, 128.6, 
140.1, 140.5, 142.8, 169.3, 172.3. 
 
2-((E)-2-((E)-4'-(2-carboxyethyl)-6-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 42: 
Yield 21%; 1H NMR (400 MHz, DMSO-d6): δ 0.39 (s, 12 H), 1.25 (m, 2 H), 1.95 (m, 6 H), 
2.30 (t, J = 7.2 Hz, 4 H), 2.75 (s, 6 H), 5.30 (d, J = 14.0 Hz, 2 H), 6.36 (m, 6 H), 6.54 (m, 6 H), 
6.72 (d, J = 8.4 Hz, 2 H); 13C NMR (100 MHz, DMSO-d6): δ 21.1, 24.2, 26.5, 29.9, 30.3, 35.8, 
99.3, 110.0, 121.8, 124.4, 128.2, 128.6, 129.3, 136.7, 140.7, 141.7, 142.9, 148.3, 172.5, 174.9. 
 
 
2-((E)-2-((E)-2-(4-(2-aminoethyl)phenoxy)-3-(2-((E)-1-ethyl-3,3-dimethylindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide, 
45: Yield 92%, mp 218-221 °C; 1H NMR (400 MHz, DMSO-d6): δ 1.12-1.30 (m, 18 H), 1.90-
1.99 (m, 2 H), 2.70-2.75 (m, 4 H), 2.77-2.97 (m, 4 H), 4.20 (q, J = 6.5 Hz, 4 H), 6.20 (d, J = 
14.1 Hz, 2 H), 7.10-7.16 (m, 1 H), 7.19-7.25 (m, 1 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.37-7.41 (m, 
4 H), 7.48-7.53 (d, J = 7.5 Hz, 2 H), 7.82 (d, J = 14.1 Hz, 2 H), 7.99 (s, 2 H). 13C NMR (100 
MHz, DMSO-d6): δ 11.5, 20.1, 23.2, 27.6, 34.0, 41.3, 48.0, 99.2, 110.4, 133.7, 120.7, 121.9, 
124.2, 127.9, 129.8, 122.7, 140.4, 141.1, 145.3, 157.5, 162.3, 170.5. HRMS m/z: calc. for 
C42H50N3O
+ 612.3949, obsd 612.3951; calc. for C42H51N3O2
+ 306.7011, obsd 306.7009. 
7.3 Optical and Physicochemical Properties   
All optical measurements were performed in phosphate-buffered saline (PBS), pH 7.4, 
100% FBS supplemented with 50 mM HEPES, pH 7.4, methanol (MeOH), ethanol (EtOH) and 
DMSO after preparing 3 mM stock solutions in DMSO. Samples were also diluted in saline 
containing 10% FBS to confirm aggregation and precipitation in solvent mixtures. UV-
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Vis/NIR absorption spectra were recorded on a Cary 50 spectrophotometer (Varian, Palo Alto, 
CA, USA) interfaced with Cary WinUV Scan Application v3.00 using VWR disposable 
polystyrene cuvettes with a 1 cm pathlength. Laser Induced Fluorescence (LIF) emission 
spectra were acquired using Shimadzu RF-5301 Spectroflurophotometer (Shimadzu 
Corporation Analytical Instruments Division, Duisburg, Germany) interfaced to a PC with RF-
5301PC software using Sigma-Aldrich disposable polystyrene fluorimeter cuvettes with a 1 
cm pathlength. All spectral measurements were recorded at room temperature. The data 
analysis and calculations were carried out using Microsoft Excel (Microsoft Corporation, 
Redmond, WA, USA). For fluorescence quantum yield (QY) measurements, oxazine 725 in 
ethylene glycol (QY = 19%) and ICG in DMSO (QY = 13%) were used as calibration 
standards, under conditions of matched absorbance at 655 and 765 nm. In silico calculations 
of physicochemical properties such as molecular weight, charge, distribution coefficient (logD 
at pH 7.4), pKa, refractivity, topological polar surface area (TPSA), H-bond donors/acceptors, 
and rotatable bonds were calculated using JChem calculator plugins (ChemAxon, Budapest, 
Hungary). Data plotting was performed using Prism version 4.0a software (GraphPad, San 
Diego, CA) and Microsoft Excel (Redmond, WA). 
7.4 Animal Models 
Animals were housed in an AAALAC-certified facility and were studied under the 
supervision of BIDMC IACUC in accordance with the approved institutional protocol (#101-
2011 for rodents and #046-2010 for pigs. Male CD-1 mice weighing ~25 g and male Sprague-
Dawley (SD) rats weighing ~250 g (Charles River Laboratories) were anesthetized with 100 
mg/kg ketamine and 10 mg/kg xylazine intraperitoneally (Webster Veterinary, Fort Devens, 
MA). Female Yorkshire pigs (E.M. Parsons and Sons) averaging 35 kg were induced with 4.4 
mg/kg intramuscular Telazol (For Dodge Labs) intubated and maintained with 2% isoflurane 
102 
 
(Baxter Healthcare). After anesthesia, EKG, heart rate, pulse oximetry and body temperature 
were monitored throughout surgery.  
7.5 NIR Fluorescence Imaging System 
The dual-NIR channel FLARE imaging system has been described in detail.10,151,152 In 
this study, 4 mW/cm2 of 670 nm excitation and 11 mW/cm2 of 760 nm excitation were used 
with white light (400–650 nm) at 40,000 lx. Color and NIR fluorescence images were acquired 
simultaneously with custom software at rates up to 15 Hz over a 15 cm diameter field of view. 
In the color-NIR merged images, 800-nm fluorescence was pseudocolored green and 700-nm 
fluorescence was pseudocolored red. The imaging system was positioned at a distance of 18 
inches from the surgical field. For each experiment, camera exposure times and image 
normalization were held constant. 
7.6 Quantitative Analysis 
At each time point, the fluorescence and background intensity of a region of interest 
over each tissue was quantified using custom FLARE software. The signal-to-background ratio 
(SBR) was calculated as SBR=fluorescence/background, where background is the signal 
intensity of neighboring tissues, such as muscle or skin, measured over the imaging period. All 
NIR fluorescence images for each particular fluorophore were normalized identically in all 
conditions of a given experiment. At least three animals were analyzed at each time point. 
Results were presented as mean +/- sd and curve fitting was performed using Prism version 
4.0a software (GraphPad). Statistical analyses were carried out using one-way analysis of 
variance followed by Tukey's multiple comparisons test. Statistical analysis was carried out by 
using the unpaired Student’s t-test or one-way analysis of variance (ANOVA). Results were 
presented as mean +/- SD and curve fitting was performed using Prism version 4.0a software 
(GraphPad, San Diego, CA). One-way ANOVA was used for statistical evaluation. P values 
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less than 0.05 were considered significant: *P < 0.05, **P < 0.01 and ***P < 0.001. The 
experiments were not randomized, and the investigators were not blinded to allocation during 
experiments and outcome assessment. 
7.7 Histology and NIR Fluorescence Microscopy 
Tissues from rats and pigs were preserved for hematoxylin and eosin (H&E) staining 
and NIR fluorescence microscopic assessment. Tissues extracted from the animals after 
intraoperative imaging were placed in 2% paraformaldehyde in PBS for 30 min before 
mounting in Tissue-Tek OCT compound (Fisher Scientific, Pittsburgh, PA) and flash-freezing 
in liquid nitrogen. Frozen samples were cryosectioned (50 μm per slice for parathyroid and 10 
mm per slice for cartilage), observed by fluorescence microscopy and then stained with H&E. 
NIR fluorescence microscopy for resected tissues was performed on a Nikon Eclipse 
TE300 microscope system with four filter sets as previously described.153,154 The microscope 
was equipped with a 100-W mercury light source (Chiu Technical Corporation), NIR-
compatible optics, a NIR-compatible 10× Plan Fluor objective lens and a 100× Plan Apo oil 
immersion objective lens (Nikon). Images were acquired on an Orca-AG (Hamamatsu). Image 
acquisition and analysis was performed using iVision software (BioVision Technologies). Two 
custom filter sets (Chroma Technology Corporation, Brattleboro, VT) composed of 650 +/- 22 
nm and 750 +/- 25 nm excitation filters, 675 nm and 785 nm dichroic mirrors, and 710 +/- 25 
nm and 810 +/- 20 nm emission filters were used to detect 26i signals in the frozen tissue 
samples. A custom filter set (Chroma Technology Corporation) composed of 750 +/- 25 nm 
excitation filters, 785 nm dichroic mirrors, and 810 +/- 20 nm emission filters were used to 
detect T800-F signals in the frozen tissue samples. 
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7.8 Live cell labeling and in vitro imaging  
Human prostate cancer cells (PC3 cells) were seeded into 24-well plates (5×104 cells 
per well), and incubated at 37 °C in humidified 5% CO2 incubator in DMEM containing 10% 
FBS and 1% penicillin streptomycin for 2 days. After washing twice with media solution, 45, 
IR786, and 32 were added to each well at a concentration of 2 µM and incubated for 30 min at 
37 °C. In order to improve image contrast, cells were washed three times with media solution 
prior to imaging. The images were acquired either right after washing or additional washing 
with 1% Tween 20 to compare fluorescent signal reduction among the contrast agents. The live 
cell imaging was performed using Nikon TE2000 epifluorescence microscope equipped with a 
75W Xenon light source and an Orca-ER (Hamamatsu, Bridgewater, NJ) camera. The filter set 
(Chroma Technology Corporation, Brattleboro, VT) composed of 710 +/- 25 nm excitation 
filter, 785 dichroic mirror, and 810 +/- 20 nm emission filter was used to detect all NIR 
fluorophores. These cells were observed again after 2 days to compare long-term stability.  
7.9 In vivo cell tracking and histological analysis 
Animals were housed in an AAALAC-certified facility and were studied under the 
supervision of BIDMC IACUC in accordance with the approved institutional protocol (#057-
2014). 6 weeks old C57BL/6 mice (male; 20-25 g) were purchased from Charles River 
Laboratories (Wilmington, MA). Animals were anesthetized with 100 mg/kg ketamine and 10 
mg/kg xylazine intraperitoneally (Webster Veterinary, Fort Devens, MA). B16F10 cells were 
stained with 2 µM of CTNF126 or IR786 for 30 min at 37 °C, and detached with cell scraper. 
1×106 cells per mouse were injected intravenously into the mice, respectively. Animals were 
sacrificed 5 min and 24 hours post-injection of the cells, respectively. The lung cavity was 
opened to observe injected cells in the lung using our custom-built intraoperative NIR imaging 
system, which equipped 760 nm excitation light (3.6 mW/cm2) and white light (400–650 nm) 
at 5500 lux. Color and NIR fluorescence images were acquired simultaneously with custom 
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software at rates of up to 15 Hz over a field of view with a diameter of 15 cm. The lungs were 
resected and embedded in Tissue-Tek O.C.T. compound (Sakura Fineteck, Torrance, CA). The 
tissues were then cryosectioned at 10 µm interval and stained with hematoxyline and eosin 
(H&E) for further visualization with TE2000 NIR fluorescence microscope. For validation of 
fluorescent signal retention during histological analysis, we preceded a standard method using 
cell pellets. PC3 were seeded onto 100 x 15 mm petri dishes and incubated at 37 °C in 
humidified 5% CO2 incubator in the media solution until the cell confluency reached 90%. 
1×107 cells (~ 5 petri dishes) were stained with 45 or IR786 at a concentration of 2 µM and 
incubated for 30 min at 37 °C. After washing with media solution, the cells were collected 
using cell scraper and centrifuged at 1200 rpm for 10 min. After the same histological 
preparation was conducted, the sectioned slides were imaged using the microscope using 20X 
objective. 
7.10 DNA Binding Studies 
A stock solution of each dye (1x10-4 M) and ct-DNA type 1 (7.5x10-3 M) were prepared 
in EtOH and Tris-HCl buffer solution, respectively. Fluorescence titration with ct-DNA 
concentrations (0-200 mM) were made by mixing 35 μL dye solution with Tris-HCl buffer 
solution with and without ct-DNA to a total volume of 3500 μL in a fluorescence cuvette to 
make working solutions of 10 μM. Fluorescence spectra were measured in duplicate with 
excitation at 530 nm and slit widths of 5 nm for both excitation and emission. 
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APPENDICES 
The following appendices contain the supplemental information including NMR and MS. 
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